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CELL TYPE DEPENDENT EFFECTS ON HSV TRANSCRIPTION 
Justine M. Harkness 
University of Pittsburgh, 2015 
Herpes Simplex Virus type 1 (HSV-1) infects both epithelial cells and neurons during the course 
of its lifecycle. Transcription of viral genes relies heavily on the cellular transcription machinery 
and chromatin remodeling complexes. Differences in the expression of transcription factors and 
in the epigenetic landscape in these two cell types could affect the ability of the virus to 
transcribe its genes and to reactivate from latency. To determine how cell type affects viral gene 
expression, RNA sequencing was used to quantify differences in viral transcription from wild 
type and mutant viruses in neurons and MRC5 cells. To ascertain if differences in the cellular 
epigenetic landscape affect the ability of the virus to reactivate, an in vitro model of latency was 
used in which viral genomes persist in a quiescent state and acquire chromatin modifications 
similar to in vivo latency. Adenovirus vectors were used to deliver the viral activators ICP0 and 
ICP4 to quiescently infected cells to determine if they could induce transcription from quiescent 
genomes. RNA sequencing and ChIP were used to quantify viral transcription and the binding of 
ICP4 to the genome. From these studies, it was concluded that i) viral gene expression from a 
mutant virus devoid of immediate early gene expression was highly repressed and dysregulated, 
ii) expression from this virus was greater in neurons than in MRC5 cells, iii) ICP4 was unable to
bind to or induce expression from quiescent genomes in MRC5 cells in the absence of ICP0, iv) 
ICP0 removes repressive chromatin, enabling ICP4 to function on quiescent genomes in MRC5 
cells, and v) ICP4 can bind to and induce transcription from quiescent genomes in neurons in the 
absence of ICP0.  
v 
The results of these studies suggest that in the absence of immediate early gene 
expression, transcription from the genome is highly dysregulated and repressed. However, the 
degree of repression differs between cell types. Neurons were more permissive to transcription, 
suggesting that they are less able to repress the viral genome. Furthermore, the viral transcription 
factor ICP4 was unable to access repressed genomes in MRC5 cells due to the presence of 
chromatin on the genome. However, ICP4 was able to access some regions of repressed genomes 
in neurons, suggesting that the form of chromatin on these genomes is less repressive and is not 
uniform throughout the genome. Together, these data imply that neurons are less efficient in 
repressing the viral genomes, and this may allow for a finer balance of latency vs. reactivation 
based on the expression of viral activators and the latency associated transcript.  
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1.0 INTRODUCTION 
Herpes Simplex Virus (HSV) infection causes a wide variety of pathologies, ranging from the 
common cold sore to a potentially fatal encephalitis. A significant percentage of the global 
population is infected, largely due to the ability of the virus to persist throughout the life time of 
the host and reactivate from latency to initiate another round of productive infection and spread. 
Both the lytic and latent portions of the virus lifecycle are regulated by the complex interplay of 
cellular and viral factors to promote or repress gene expression. During all phases of its lifecycle, 
cellular chromatin is present on the viral genome and modulates gene expression. During lytic 
infection, nucleosomes are acetylated and randomly dispersed on the viral genome, characteristic 
of the active form of chromatin known as euchromatin. However, during latent infection, the 
viral genome is repressed by densely packed nucleosomes rich in histone methylation, 
characteristic of the repressive from of chromatin known as heterochromatin. During reactivation 
of the virus, the epigenetic state of the virus shifts from heterochromatic to euchromatic to enable 
viral lytic gene expression to resume and likely is mediated by a combination of viral and 
cellular proteins. An understanding of the ability of viral activators to function on partially 
heterochromatic genomes will provide greater insight into the process of reactivation. Thus, this 
introduction will discuss the two distinct stages of the viral life cycle and reactivation, with a 
particular emphasis on the chromatin control of the viral lifecycle. Additionally, an overview of 
the different states of chromatin and the complexes responsible for their establishment will be 
discussed.  
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1.1 PATHOLOGY AND VIRUS STRUCTURE 
1.1.1 The Herpesviridae Family 
Herpes Simplex Virus 1 is a member of the family Herpesviridae, which encompasses the 
herpes viruses that infect mammals, birds, and reptiles. To date, nine herpes viruses have been 
identified that infect humans, but greatly differ in their host cell range and disease presentation. 
These nine herpes viruses can be further subdivided into three groups based on their 
biological properties: alphaherpesvirinae, betaherpesvirinae, and gammaherpesvirinae. 
Alphaherpesviruses are characterized by a wide host range, short reproductive cycle, killing 
of host cells, and ability to establish latent infection, mainly in sensory ganglia. HSV-1 and 
HSV-2 as well as the chicken pox virus Varicella Zoster Virus (VZV) are in this subfamily. 
Betaherpesviruses tend to have a more restrictive host range and a longer replication cycle, 
and establish latency in multiple tissues including lymphoid tissue, secretory glands, and 
kidneys. Infected cells often become enlarged and carrier cells can be easily 
established. Members of this family include cytomegalovirus (HCMV), the two 
variants of Roseolovirus (HHV-6A&B) and HHV-7. Gammaherpesviruses primarily infect 
lymphoid cells, but some members can also replicate in specific types of epithelial cells and 
fibroblasts in vitro. These viruses will usually infect and establish latency in either T or B 
cells. Epstein-Barr virus (EBV), the causative agent of mononucleosis, and Kaposi's 
sarcoma-associated herpesvirus (KSHV or HHV-8), an oncogenic virus which commonly 
induces sarcomas in immunocompromised patients, are members of this family.  
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All herpesviruses share 4 significant biological properties: i. they specify their own set of 
enzymes involved in nucleic acid metabolism, DNA replication, and protein processing; ii. they 
transcribe genes, replicate DNA, and assemble nucleocapsids in the host cell nucleus; iii. lytic 
replication and production of progeny virions kills the infected cell; and iv. they establish a latent 
infection and persist throughout the life of the host. The remainder of this introduction will focus 
specifically on HSV-1.  
1.1.2 HSV-1 Viral and Genome Structure 
The general structure of a Herpes Simplex Virus is shown in cartoon form in Figure 1. 
All herpesviruses share a similar structure, but vary in overall size due to differences in 
tegument thickness. Cyro-Electron Microscopy studies have estimated the size of the HSV-1 
virion to be 168nm in diameter, 225nm with the glycoprotein spikes included [1]. The viral 
particle consists of 4 main parts. At the very core of the virus is the genome, a strand of 
double stranded DNA that is densely packed in a toroid structure within the viral capsid 
with polyamines to reduce electrostatic repulsion from the DNA backbone [2, 3]. The 
dense packing of the genome is theorized to aid the injection of the viral DNA into the 
nucleus during uncoating [4]. The viral capsid has a T=16 icosahedral symmetry and consists 
of 162 capsomeres, including 150 hexons, 11 pentons, and the portal protein [5]. It is 
composed of four main structural proteins, VP5, VP26, VP23, and VP19C [6]. Between the 
capsid and the envelope is the viral tegument, an unstructured layer consisting of at least 18 
proteins. The most notable of these proteins are VP16, the inducer of viral immediate early 
transcription, and virion host shutoff protein (VHS), which ceases translation of host cell 
proteins. The exterior layer of the virus is the viral envelope which 
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is studded with at least 13 glycoproteins, many of which are involved in cell entry. The lipids 
composing the viral envelope are believed to originate from the cytoplasmic membrane [7].  
Figure 1: HSV Virion Structure 
Cartoon representation of HSV-1 viral particle, adapted from [8] 
The herpes virus genome is a linear double strand of DNA of approximately 150 kilobase 
pairs [9]. The exact length of the genome varies between isolates due to differences in the 
number of a sequences and length of the inverted repeats. A schematic of the structural 
composition of the genome is shown in Figure 2. The genome can be thought of as two 
segments, the unique long and unique short regions, flanked and joined by repeated regions [10]. 
The unique long and short regions contain the majority of viral genes, and each gene on these 
segments is present only once. The repeat regions contain sequences for DNA packaging and 
also contain some viral genes, mainly those that encode immediate early proteins. Since these 
regions are present twice in the genome, genes within the repeat regions are present in duplicate. 
Furthermore, the presence of the repeated regions enables recombination during replication, 
leading to 4 possible orientations of the L and S segments in equimolar amounts [11]. The 
internal repeat sequences can be deleted to prevent recombination, but this does prohibit 
replication in cell culture [12].  
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The viral genome contains 85 protein coding genes that are very densely packed. Despite 
the dense packing, these genes have their own unique promoters responsive to both viral and 
cellular transcription factors and are transcribed by the host cell RNA polymerase II [13]. To fit 
all of these genes in such a short sequence of DNA, many genes are oriented antiparallel and 
transcribed from opposite strands of DNA. Some genes will also produce a transcript that 
encodes multiple proteins that are proteolytically cleaved upon translation [14]. Other genes may 
also share a common 3’ terminal end, but initiate transcription at different start sites [15-18]. 
Unlike cellular genes, most viral genes do not require splicing; only the ICP0, ICP27, ICP22, 
UL15, and LAT transcripts are spliced.  
Figure 2: Structure of HSV-1 Genome. 
The genome contains unique long and unique short regions, which are flanked by repeated 
sequences. During DNA replication, recombination occurs between these repeated sequences, 
yielding four different configurations of the genome in equimolar amounts, adapted from [19] 
1.1.3 HSV-1 Prevalence and Pathology 
HSV-1 has been documented in the human population as early as the ancient Greek 
times. Hippocrates first described the cutaneous spreading HSV lesions, leading Greek 
scholars to define the term herpes to mean “to creep or crawl.” However, the transmission of 
the virus from one individual to another was not recognized until 1893. HSV research 
blossomed in the twentieth century and in 1919, the infectious nature of HSV was 
experimentally confirmed by Lowenstein [20].  
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Herpes simplex virus remains highly prevalent in the human population to this day. It has 
been estimated that approximately 90% of the population is seropositive and nearly 85-90% of 
trigeminal ganglia contain herpes DNA at autopsy [21, 22]. This high prevalence among the 
population can be attributed to the ability of the virus to establish a persistent infection in the 
host, where the virus remains latent in the ganglia and periodically reactivates to cause 
recrudescent disease and spread. HSV can cause a primary infection in epithelial cells, including 
the oral mucosa, skin, and genital tract. Infection of the oral mucosa leads to the development of 
herpes labialis, which manifests as small blisters on the lips and mouth. Recently, HSV-1 has 
become the more prevalent cause of herpes genitalis in the younger population, likely due to 
changes in sexual behavior, reviewed in [23]. The virus can also infect other cutaneous areas of 
the body. Before the wearing of gloves was common practice, herpes whitlow, an infection of the 
fingers, was common in dentists and dental hygienists [24]. Additionally, many wrestlers are on 
prophylactic valacyclovir treatment to prevent the development of herpes gladiatorum, an 
infection of the skin. It has been estimated that approximately 40% of wrestlers are infected [25].  
The virus can cause more severe conditions, depending on both the site of infection and 
immune competency of the host. When inoculated through an ocular route, the virus can induce 
inflammation of the cornea through repeated rounds of reactivation, causing stromal keratitis 
[26]. Herpes stromal keratitis is the leading cause of infectious blindness, affecting 
approximately 1.5 per 1000 people [27]. While affected individuals require corneal transplants, 
there is no difference in transplantation efficacy between herpetic and non-herpetic stromal 
keratitis, indicating that the presence of infection does not negatively impact the transplant in the 
short term [28].  
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In both ocular and oral routes of infection, the virus can spread from the primary site of 
infection through the ganglia to infect the central nervous system and cause a potentially fatal 
encephalitis. It has been estimated that herpes virus encephalitis constitutes approximately 20% 
of the total cases of encephalitis and affects 1 in 250,000-500,000 individuals annually [29, 30]. 
Left untreated, the infection has a 70% mortality rate. The standard treatment is intravenous 
acyclovir, but mortality remains high at 30% and many survivors are left with neurological 
impairments [31].  
In addition to causing pathology on its own, HSV can synergize with HIV in co-infected 
individuals, exasperating the replication and spread of both viruses. Studies of co-infected 
patients have shown that HIV shedding is greatly increased during clinical HSV reactivation in 
the genital tract [32]. The open sores caused by HSV also enhance the transmission of HIV. 
Furthermore, the enhanced replication of HIV during active HSV disease has been shown to be 
independent of the immune state of the host, implicating HSV as the driving factor [33]. HIV 
infection also enhances the replication and spread of HSV through disruption of tight and 
adherence junctions at the oral mucosa [34]. Immunocompromised individuals, such as those 
with HIV, are at an increased risk of developing drug resistant HSV strains, making treatment of 
these individuals more challenging [35]. 
1.1.4 HSV as a Gene Therapy Vector 
Despite all of the sometimes severe diseases the virus can induce, several decades of 
research into the HSV virus and progress in recombinant DNA technology has led to the 
development of HSV as a vector for multiple applications to benefit human health. Uses 
for HSV vectors 
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include: i delivery and expression of genes in neuronal tissues; ii targeting and destruction of 
cancer cells; iii immunotherapy against tumors; and iv potential vaccine development [36-38]. 
Because the genome is very large and encodes many non-essential genes, regions of the genome 
can be deleted and replaced with exogenous DNA sequences, up to 40-50kb, for multiple 
purposes [39]. However, the deletion of viral genes to improve safety can result in a loss of viral 
activities necessary for efficient gene delivery and prolonged expression in the host. There are 
currently three different types of vectors used that have been designed to overcome some of 
these challenges: amplicon vectors, replication-deficient vectors, and replication competent 
vectors with a restricted host cell range [40]. 
 Amplicon vectors are structurally identical to wild type virus, containing all of the same 
structural proteins, but have an entirely different genome devoid of any viral genes. Amplicons 
are made by transfecting cells will the amplicon plasmid, then superinfecting with a HSV-1 
helper virus which will encode all of the proteins necessary for viral packaging. To prevent 
contamination of amplicon stock with helper virus, the genome of the helper virus lacks 
packaging sites to prevent encapsidation of the genome [41]. Additional improvements on this 
system include deletion of y34.5 and ICP4, a virulence factor and essential transcription factor, 
respectively [42]. Since these vectors are effective at delivering genes, but are diluted out as cells 
divide, they are best suited for acute applications, and have been used for pain management and 
anti-cancer therapies [43, 44]. 
 Replication deficient vectors are created by knocking out viral genes that are essential to 
the replication of the virus. Deletions of the viral immediate early proteins ICP4 and ICP27 is 
sufficient to render the virus incompetent for replication, and these knockout viruses can be 
grown on complementing cell lines. Replication deficient viruses will infect cells and establish a 
9 
lifelong infection, enabling long term expression of genes. Furthermore, insertion of genes into 
the LAT locus can promote lasting specific expression in neuronal cells [45]. Recombinant 
viruses have been shown to prevent lethal challenges of infection when used as a vaccine and can 
promote a lasting immunity [46, 47]. Preclinical studies have also shown that these vectors can 
be used to deliver growth factors to nerves to treat peripheral neuropathy caused by several 
factors [48].  
Replication competent viruses are the most effective at delivering a transgene in that a 
small population of infected cells is sufficient to allow spread to more cells. In these viruses, the 
essential genes are left intact while some virulence genes – including thymidine kinase, 
ribonucleotide reductase, y34.5, and virion host shutoff protein – are deleted. The first attenuated 
HSV virus to be characterized and analyzed as a vaccine was NV1020 [49, 50]. Since then, 
attenuated viral strains have become an attractive means of creating oncolytic viruses. The 
surface glycoproteins can be modified to target the virus to specific cell types. Recent studies 
have shown that an oncolytic virus specific to hepatocarcinoma cells can result in tumor 
regression in a mouse model [51]. Furthermore, several promising oncolytic viruses are currently 
in clinical trials [52-54].  
1.2 LYTIC REPLICATION 
1.2.1 General Overview 
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A schematic of the lytic replication cycle is shown in Figure 3. The virus first enters the cell 
through attachment to various receptors followed by fusion of the viral envelope to the cell 
plasma membrane or endocytosis. The viral capsid is released into the cytoplasm and travels 
along microtubules in an energy dependent manner to the nuclear pore where it docks, releasing 
viral DNA and some viral proteins into the cell nucleus. Viral gene expression begins when the 
viral transactivator VP16 complexes with two cellular proteins, Oct-1 and HCF, and induces 
expression of immediate early proteins, including ICP0 and ICP4 [55]. ICP0 functions to 
counteract the cellular innate immune response and maintain the viral genome in a euchromatic 
state. ICP4, the main viral transcription factor, induces the expression of early genes and 
represses the expression of immediate early genes [56, 57]. Early gene products mainly include 
proteins required for replication of the viral genome. DNA replication begins approximately 4 
hours post infection and proceeds by a rolling circle or recombination based mechanism, 
producing long concatamers of viral DNA.  
Following DNA replication, ICP4 induces the expression of late genes, which encode the 
structural proteins of the virus. The immediate early protein ICP27 also functions to promote the 
expression of late genes and some early genes. Late gene products are transported back into the 
nucleus and viral capsids are assembled. The viral DNA is cleaved into genome length segments 
and packaged into preformed capsids [58]. The capsids bud into the ER and acquire their 
envelope studded with viral glycoproteins. The viral particles then exit the ER through budding, 
acquiring a second membrane, travel through the golgi complex, and then exit the cell through 
fusion with the plasma membrane. The mature virus will consist of a viral capsid, tegument, and 
viral envelope. Following replication in epithelial cells, the virus can spread to surrounding 
epithelial cells or gain access to the ganglia through neurons innervating the primary site of 
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infection. A more detailed description of the different stages of the viral lifecycle including 
entry, viral gene transcription, DNA replication, capsid assembly, and chromatin dynamics is 
presented in the following sections.  
Figure 3: Lytic Replication Cycle of HSV-1. 
1. The viral particle binds to surface proteins and enters the cell through fusion of the viral
envelope to the plasma membrane. 2. The viral capsid and associated tegument proteins are
transported to the nuclear pore. 3&4. Immediate early genes are expressed and translated. 5&6.
Early genes are expressed and translated. 7. Viral DNA is replicated, inducing the expression of
late genes. 8. Late gene transcripts are translated. 9. Capsid assembles, followed by DNA
packaging. 10. Viral capsids bud into ER and acquire glycoproteins. 11. Viral particles bud out
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of ER. 12. Viral particles move through the golgi complex. 13. Infectious virions are released 
from the cell.  
1.2.2 Viral Entry 
HSV-1 has a very broad range of cells that it can infect due to multiple receptors that the 
viral glycoproteins can bind: heparin sulfate, HVEM, and nectin-1. The HSV-1 envelope is 
studded with 12 different glycoproteins. However, only 7 of these 12 are necessary and 
sufficient for virus entry; these glycoproteins include gB, gC, gD, gH, gK, gL, and gM. The 
first step in entry is the attachment of the virion to the cell surface through interactions of gB 
and gC with heparin sulfate on the cell surface. Heparin sulfate is a proteoglycan that is found 
on the cell surface of most cell types [59]. It is composed of a polyanionic carbohydrate chain 
of 10-200 disaccharides covalently linked to a protein core and can be further modified by 
multiple glycosyltransferases in the cell [60]. Both gB and gC can bind heparin sulfate, but 
gB binds with a higher affinity [61]. While gC can enhance the binding, it is not necessary for 
attachment. This interaction with heparin sulfate mainly functions to tether the virion to the cell 
surface and alone is not sufficient for cell entry. However, the 3-O-sulfated isoform of heparin 
sulfate can directly interact with gD to function as a true receptor for cell entry [62].  
In addition to the 3-O-sulfated isoform of heparin sulfate, gD can also interact with 
herpes virus entry mediator (HVEM) and nectin-1 to induce membrane fusion and cell entry. 
HVEM is a member of the TNF/NGF receptor family and is primarily expressed on the surface 
of immune cells [37, 63]. While this receptor is sufficient for viral entry, T cells are not a target 
of the virus. Rather, the interaction of HSV-1 (and HSV-2) with this receptor is believed to 
modulate the host immune response to the virus [40]. Nectin-1, a cell adhesion molecule that is 
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abundantly found on epithelial cells and neuronal synapses, is the more commonly used receptor 
for viral entry [64, 65]. It is sufficient for viral spread from the cornea to the ganglia [40], but the 
presence of only nectin-1 leads to attenuation of viral spread [66].  
The binding of gD to its receptor triggers conformational changes in the protein, exposing 
an interaction site to bind to the dimeric gL/gH complex. This interaction induces a 
conformational change in gL/gH that triggers the conversion of gB into its fusogenic state. The 
fusion loops of gB are inserted into the cellular plasma membrane, leading to the fusion of the 
cell membrane with the viral envelope, reviewed in [41]. Following fusion, the viral capsid is 
released into the cytoplasm. The viral capsid is transported to the nucleus through interactions 
with microtubules via the motor protein dynein [46]. The capsid docks to the nuclear pore, likely 
through interactions between tegument proteins and cellular proteins. The mechanism of 
uncoating at the nuclear pore is still unclear [44]. The viral DNA is then translocated into the 
nucleus where transcription of viral genes occurs. 
1.2.3 Viral Gene Expression 
The expression of viral genes occurs through a very tightly controlled cascade of RNApol II 
mediated transcription [13], depicted below in Figure 4. The tight regulation of transcription is 
partly due to differences in the architecture of promoters of genes from different kinetic classes. 
A schematic of these promoters is shown in Figure 5.  
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Figure 4: Lytic Gene Expression Cascade 
Viral genes are expressed in a highly regulated transcriptional cascade in which immediate early 
genes are first expressed followed by early and late genes, adapted from [67] 
The first genes to be expressed are immediate early genes, which peak in synthesis 
between 2 and 4 hours post infection and are expressed in the absence of de novo viral protein 
synthesis [68]. Immediate early promoters have binding sites for VP16 as well as several cellular 
transcription factors including NF1, Sp1 and TFIID [69, 70]. They are induced when the viral 
tegument protein VP16 enters the nucleus and forms a complex with cellular proteins HCF and 
Oct-1 and binds to TAATGARAT sequence elements on the promoter [71]. Approximately 500-
1000 copies of VP16 are found in the tegument [72]. VP16 forms contacts with several cellular 
activators to promote transcription. These specific interactions are discussed in a later section.  
VP16 functions to activate transcription of the five immediate early proteins ICP0, ICP4, 
ICP27, ICP47 and ICP22 which play a role in promoting viral transcription and disarming the 
host immune response. ICP4 is the main transcription factor of the virus and will activate both 
early and late genes and repress immediate early genes.  
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Figure 5: HSV Promoter Architecture 
Representation of promoter elements of each kinetic class of viral genes, adapted from [67] 
Following the expression of immediate early genes, early and late genes will be induced 
by ICP4. Concurrent with the activation of early genes is the ICP4 mediated repression of 
immediate early genes. ICP4 represses its own expression through binding to a strong binding 
site in the promoter downstream of the TATA box and forming a tripartite complex with TBP 
and TFIIB that blocks formation of the transcription initiation complex [73]. ICP4 binding sites 
on the ICP0 promoter upstream of the TATA box have also been identified and shown to be 
important for the repression of ICP0; however, the exact mechanism of repression of this 
promoter has not yet been elucidated [74]. Furthermore, viruses in which ICP4 has been deleted 
highly overexpress the other immediate early genes, indicating that other mechanisms exist for 
repression [56].  
Early genes are maximally expressed between 4 and 6 hours post infection. The 
promoters of early genes lack TAATGARAT elements and are thus not responsive to VP16 
activation. ICP4 is the strongest inducer of expression of early genes, but some cellular 
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transcription factors are also involved. The promoters of early genes contain binding sites for the 
cellular transcription factors Sp1 and NF1, as well as a TATA box. Removal of the Sp1 sites 
leads to a 2-3 fold reduction in thymidine kinase expression, a representative early gene. Sp1 
enhances transcription by stabilizing the binding of TFIID through interactions with an 
unidentified protein [75]. However, the absence of NF1 does not alter expression from thymidine 
kinase, indicating that NF1 may not be directly required for promoting early gene expression 
[76]. The TATA box is the most important element for ICP4 mediated transcription. ICP4 binds 
to the DNA in a less specific manner through oligimerization at low affinity sites [77] and 
functions to stabilize the interaction of TFIID with the TATA box [78]. ICP4 also recruits 
mediator and other chromatin remodeling complexes to promote early gene expression [79].  
 Similar to immediate early genes, early genes are repressed following their expression. 
However, a mechanism for this repression has not yet been identified, though it is likely to 
depend on changes in the modification or abundance of cellular and viral transcription factors 
that occur during DNA replication. One possible mechanism could be changes in the 
phosphorylation of Sp1 that occur during viral DNA replication. During DNA replication, the 
cell recognizes viral DNA ends and activates the DNA damage response, consequently, the DNA 
damage response protein ATM phosphorylates Sp1 [80]. Phosphorylated Sp1 does not activate 
transcription as efficiently in vitro [81] and would likely be less efficient in activating early gene 
expression. Furthermore, the cellular general transcription factor TFIIA is degraded between 4 
and 8 hours post infection [82]. During transcription initiation, TFIIA functions to stabilize the 
binding of TBP with the promoter [83]. TFIIA has been shown to be required for the expression 
of early genes, but dispensable for the expression of late genes as the INR element can 
functionally substitute for the absence of TFIIA [84]. Because the INR element is only present in 
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the promoters of late genes, late genes but not early genes can be expressed when TFIIA levels 
are low in the cell. ICP27 also enhances the expression of late genes, possibly through linking 
PolII to progeny DNA through interactions with both the DNA binding protein ICP8 and the 
RNA polII holoenzyme [85]. 
In addition to changes in cellular transcription factors, ICP4 differently associates with 
cellular transcription factors throughout the course of lytic infection. ICP4 primarily associates 
with components of TFIID early in infection to promote gene expression. The mediator complex 
does not associate with ICP4 until later in infection, around 6 hours post infection when viral 
DNA is actively replicating. Furthermore, this form of mediator contains the kinase domain and 
lacks the component Med26 [79]. This form of mediator is generally associated with gene 
repression [86]. The transition from early gene expression to late gene expression could in part 
be due to changes in ICP4 interaction partners. ICP4 bound to TFIID can be a potent activator of 
early gene expression, but when bound to mediator, could be unable to activate early genes and 
instead transition to activate late genes.  
Late genes are expressed to their peak levels only after the viral DNA has been replicated 
after 6 hours post infection. Late genes can further be subdivided into γ1 and γ2 classes based on 
their promoter structure. Leaky late genes, γ1, can be expressed to low levels prior to DNA 
replication. Their promoters contain Sp1 sites, TATA boxes, and INR elements. True late genes, 
γ2, require DNA replication for their expression. Their promoters contain INR elements, TATA 
boxes, and downstream activation sequences (DAS). The level of expression of late genes is 
most highly correlated to the similarity of the promoter to the consensus sequence of the TATA 
box and the INR element [87]. The INR elements specify TAF1/2 binding and are required for 
the expression of the true late protein gC [88]. The DAS is not found in the promoter of all late 
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genes and is not required for the expression of genes with strong TATA boxes and INR 
elements. Rather, it functions to promote expression of genes with weak TATA boxes and INR 
elements [89], such as UL38 which has a non-consensus TATA box and requires this element for 
expression [90].  
1.2.4 DNA Replication 
The HSV genome has three origins of replication. Two are located within the short repeats 
between ICP4 and ICP22 or ICP27 and the third one is located between UL29 and UL30 in the 
unique long region (Figure 2 [91]). Although all three origins are nested between coding regions, 
they appear to play no role in transcriptional regulation of the surrounding genes [92]. Both the 
OriS origins and OriL origin contain A/T rich sequences flanked by binding sites for the origin 
binding protein UL9, but differ in their exact structure. OriS contains a 45 base pair imperfect 
palindrome flanked by two UL9 binding sites and a third weak binding site [93]. The OriS sites 
have been shown to be dispensable for DNA replication, as a mutant virus in which both OriS 
sites were deleted replicated DNA with only slightly delayed kinetics compared to wild type 
virus [94]. OriL has a 144 base pair perfect palindrome containing four binding sites for UL9 
[95, 96]. It also appears to play a more major role in DNA replication during in vivo infection, as 
mutations in OriL but not in OriS reduce pathogenesis [97]. 
DNA replication begins around 4 hours post infection after the transcription and 
translation of early genes, many of which are involved in the replication of the genome. Seven 
virally encoded genes have been identified to be required for viral DNA replication from both 
the OriL and OriS [98]. Of these seven proteins, six of them are conserved across all herpes 
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viruses and include the single strand binding protein ICP8, the two subunit DNA polymerase 
UL30 and UL42, and the helicase primase complex consisting of UL5, UL8, and UL52. The 
origin binding protein UL9 is specific to HSV-1 and HSV-2 and no clear homologs have been 
found in β and γ herpesviruses [99].  
DNA replication begins with the recognition of one or several origins of replication by 
UL9. Since UL9 is required early in replication, but not at later times, a two stage model of DNA 
replication has been suggested [100]. In the first step of replication, UL9 in complex with ICP8 
induces the destabilization of the origin of replication through slightly separating the DNA 
strands and the activation of the helicase activity of UL9, enabling recruitment of viral 
replication factors [101]. Once the origin has been activated, the helicase primase complex is 
recruited, likely through protein-protein interactions; UL9 has been shown to interact with UL8 
subunit [102]. The helicase primase complex will then unwind the double stranded DNA and 
synthesize a short RNA primer. This complex has also been suggested to function as a scaffold 
for the recruitment of additional replication factors, specifically the DNA polymerase complex 
[103]. Once recruited, polymerase will catalyze DNA synthesis on the leading and lagging 
strands. Once DNA synthesis has begun at one or more origins of replication, the process 
becomes UL9 independent and proceeds by a rolling circle and/or DNA recombination 
dependent mechanism [19, 104].  
1.2.5 Capsid Assembly and DNA Packaging 
Assembly of the capsid and DNA packing both occur in the nucleus. The virus can form 
three different forms of capsids: A, B, and C. The C capsid is the only type that has undergone 
DNA 
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packaging and is found in infectious virions. A and B capsids are both dead ends in the 
packaging process, having either failed to package DNA or failed to release the scaffolding 
protein [58]. The viral capsid is composed of multiple proteins, the majority of which are true 
late proteins. The four main structural proteins that compose the capsid are the major capsid 
protein VP5 and three less abundant proteins: VP19C, VP23, and VP26. The capsid also contains 
minor proteins including UL6, UL15, UL17, UL28, and UL33 which are required for the 
cleavage and packaging of viral DNA into preassembled capsids. The capsid has a T=16 
icosahedral lattice and is composed of 162 capsomers – 150 hexons, 11 pentons, and the portal 
where DNA enters the capsid.  
 The capsid is assembled through the use of a scaffolding protein. The scaffold protein, 
UL26.5 (VP22a), forms a core scaffold inside the capsid and interacts directly with VP5 though 
hydrophobic interactions with the N terminus of VP5. The scaffold protein has the ability to self 
interact and multimerize which drives the assembly of the capsid. As the capsid assembles, one 
portal complex, composed of 12 UL6 protein subunits, will be added through interactions with 
the scaffold [105]. The triplex, composed mainly of V19C and VP23, is added as the hexons and 
pentons assemble. VP26 will localize to the distal tips of VP5 in hexons, but not pentons. The 
formed capsid containing scaffolding protein is referred to as the procapsid, an unstable 
conformation. The procapsid can undergo a structural change prior to DNA packaging and form 
a B capsid or DNA packaging proteins can associate with the portal to begin packaging. 
 Five proteins have been shown to be necessary for DNA packaging, two of which are of 
unknown function. UL15, UL28, and UL33 comprise the terminase complex, an ATPase, which 
associates with the portal and is responsible for inserting the DNA into the capsid and cleaving 
the DNA into genome lengths [106]. The complex recognizes and cleaves specific packaging 
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signals in the viral DNA, denoted pac1 and pac2. Following packaging of the DNA, UL25 and 
UL17, the two components of the C-capsid specific component (CCSC), associate with the viral 
capsid and function to stabilize the DNA within the capsid to form a mature C capsid [107, 108]. 
In the absence of this CCSC, the DNA leaves the capsid, forming an A capsid, another dead end 
of virus assembly.  
The mature capsid will exit the nucleus through exocytosis and acquire its envelope and 
glycoproteins while budding through the inner nuclear membrane. The viral envelope fuses with 
the outer nuclear membrane, releasing the virus into the cytosol, where it will pass through the 
trans-golgi network. It will be packaged within two membranes as it leaves the golgi and will 
exit the cell through fusion of the second membrane to the plasma membrane [109]. The mature 
virion will go on to infect other epithelial cells or can enter the nerve tissue through neurons 
innervating the primary site of infection.  
1.2.6 Chromatin Dynamics during Lytic Infection 
The viral DNA in fully assembled virions is completely devoid of cellular histones. HSV 
particles were found to contain the polyamines spermine and spermidine. Spermidine was found 
to be primarily associated with the viral envelope, where as spermine was mainly found in the 
nucleocapsids, possibly due to a higher affinity for viral DNA. Furthermore, there is a constant 
molar ratio between DNA phosphate and polyamine nitrogen, suggesting that the DNA is 
packaged with the polyamines, primarily spermine, to stabilize the viral DNA through 
neutralization of the negatively charged phosphate backbone, similar to T4 phages [3].  
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However, when the viral DNA enters the nucleus, cellular histones are deposited onto the 
genome. Histone deposition and removal is regulated by several factors, including localization of 
the incoming viral genome, cellular chromatin modifiers, and viral proteins. The viral genome is 
localized to the nuclear periphery through interactions with type A lamins. This localization is 
correlated to a reduction in heterochromatin deposition, measured by H3K9 and H3K27 
trimethylation, on viral genomes early in infection [110].  
 Two different cellular complexes can localize to viral genomes and deposit histones: 
hDaxx/ATRX and HIRA/Asf1. Early during infection, the major ND10 complex proteins PML, 
Sp100, and hDaxx rapidly re-localize to viral genomes [111]. HDaxx functionally interacts with 
the SWI/SNF chromatin remodeler ATRX to deposit H3.3 containing histones on viral DNA. 
[112]. hDaxx functionally interacts with HDAC2 and Dek, a protein that has been shown to 
change the topology of chromatin and block DNA replication and could possibly impair 
transcription [113, 114]. Chromatin deposition by the hDaxx ATRX complex ultimately leads to 
the formation of heterochromatin, likely aided by other proteins localized to ND10 such as 
Sp100. 
On the other hand, Asf1 and HIRA mediated histone deposition promotes HSV lytic 
infection. Depletion of Asf1 from cells led to an increase in the expression of immediate early 
genes, but not early and late genes. Despite the increase in immediate early gene expression, 
there was a decrease in viral DNA replication and viral yield, indicating that Asf1 is important in 
promoting HSV DNA replication and virus production [115]. Asf1 forms a complex with HIRA 
to promote the deposition of H3.3 in a DNA replication independent manner [116]. HIRA has 
been shown to deposit H3.3 histones onto viral DNA early in infection and the incorporation of 
H3.3 correlates with higher gene expression. Knockdown of HIRA leads to a decrease in H3.3 
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occupancy on the genome and lower levels of gene expression and viral replication. HIRA is not 
required for the incorporation of H3.1 containing nucleosomes, which are added to the genome 
in a DNA replication dependent manner [117]. The localization of the viral genomes to either of 
these two complexes may determine the initial epigenetic state of incoming genomes. 
There are also several cellular complexes that modify viral chromatin to either activate or 
repress viral transcription. These complexes are shown in Figure 6. Expression from the viral 
genome is silenced through the deposition of repressive heterochromatin marks, notably H3K9 
and H3K27 trimethylation. The polycomb repressive complex 2 methylates H3K27 residues 
during latent infection [118] and is likely, but has not shown to be, responsible for this 
methylation early in lytic infection. The methylase responsible for methylating H3K9 during 
infection has not yet been identified, though Suv39h1 is a potential candidate. The 
chromodomain helicase DNA-binding (CHD) nucleosome remodeler family member proteins 
CHD1 and CHD3 can then bind to trimethylated H3K9 and H3K27 and promote the compaction 
of viral chromatin [119]. In addition to depositing silencing marks onto the genome, other 
cellular complexes remove activating marks for viral chromatin. The CoREST complex consists 
of the REST and CoREST proteins in complex with HDACs1 and 2 as well as LSD1. In this 
complex, HDAC1 stimulates the demethylase activity of LSD1 to remove the activating H3K4 
methylation [120, 121].  
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Figure 6: Chromatin Modifiers 
Complexes involved in depositing or removing silencing marks on the HSV genome during lytic 
replication, adapted from [122] 
To counteract the deposition of silencing chromatin early in infection, viral transcription 
factors actively recruit cellular histone remodeling complexes to viral genomes and disable 
silencing factors to remove silencing modifications and add activating modifications. VP16 
interacts with Oct-1 and HCF to induce expression of immediate early genes, while removing 
repressive chromatin from the genome. HCF-1 serves as a scaffold for the recruitment of various 
viral and cellular proteins and is required for effective transcription of immediate early genes 
[123]. HCF-1 interacts with and recruits the Set1 and MLL1 complexes as well as the 
demethylases JMJD2 and LSD1 to catalyze the removal of methylation from H3K9 and promote 
the methylation of H3K4. The proteins in the Set1/MLL/JMJD2/LSD1 complex cooperate in a 
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step wise manner to first demethylate H3K9 and then methylate H3K4. The demethylation of 
H3K9 is driven by JMJD2 and LSD1. The JMJD2 family of proteins can demethylate 
trimethylated H3K9, where as LSD1 can only demethylate mono and dimethylated H3K9, thus 
JMJD2 function is a prerequisite for the action of LDS1 [124]. Knockdown of either of these 
proteins leads to an increase in repressive chromatin on viral promoters and a decrease in viral 
gene expression [125, 126]. Once H3K9 methylation has been removed, the Set1 or MLL1 
complex will methylate H3K4. Both complexes are recruited by HCF-1 to immediate early 
promoters [127]. Knockdown of Set1 led to a decrease in H3K4 methylation, demonstrating Set1 
was required for this methylation [128]. 
Other chromatin remodelers are recruited to viral genomes independent of interactions 
with the VP16 activator complex. SNF2H, a member of the ISWI family of chromatin 
remodeling enzymes, was found to be localized to viral replication compartments [129]. SNF2H 
was found to be associated with the viral genome when immediate early genes are expressed and 
declined as infection progressed to late gene expression. Furthermore, in the absence of SNF2H, 
immediate early gene expression was significantly decreased while histone association increased, 
suggesting that SNF2H functions early in infection to enhance the expression of immediate early 
genes to drive lytic replication [130].  
The CLOCK acetyltransferase has also been shown to be recruited to the viral genome at 
ND10 bodies and is stabilized during infection. Furthermore, knock down of CLOCK during 
infection led to a decrease in gene expression indicating that it promotes viral gene expression. 
Overexpression of CLOCK, but not a catalytically dead mutant was also shown to partially 
compensate for ICP0 during infection with an ICP0 null virus, indicating that the histone 
acetylase activity of CLOCK is required to promote gene expression [131]. ICP0 also functions 
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independent of VP16 to counteract cellular repressors through catalyzing the addition of 
uniquitin to substrates and targeting them for degradation by the cellular proteosome. The many 
proteins that ICP0 targets are discussed in the next section under the function of ICP0 as a viral 
activator.  
The synergistic functioning of these viral activators and cellular chromatin remodeling 
complexes leads to a euchromatic viral genome. Multiple studies using micrococcal nuclease, a 
nuclease that cleaves regions of DNA between nucleosomes, have shown that during lytic 
infection HSV DNA was not organized into nucleosomes [132, 133]. More recent studies have 
shown that HSV DNA is associated with nucleosomes-like complexes throughout lytic infection, 
but they are unstable [134]. Furthermore, histones associated with viral genomes are modified in 
ways that promote viral transcription. Histones are acetylated at positions H3K9 and H3K14 
during lytic infection, and H3K4 is methylated [135].  
1.3 VIRAL ACTIVATORS 
1.3.1 VP16 
VP16 is a 490 amino acid protein containing 2 functional domains, the core domain and the 
C terminal activation domain, Figure 7A. The core domain resides in the center of the 
protein, is required for DNA binding, and is conserved among many alpha herpes viruses [55]. 
It has both structured and unstructured regions; the structured region recognizes and 
binds the TAATGARAT consensus sequence, while the unstructured region interacts with 
Oct-1 and HCF to stabilize the binding of VP16 to the DNA [136, 137]. The activation 
domain is enriched in 
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acidic residues and resides in the 81 C terminal amino acids. It can further be divided into two 
distinct regions, H1 and H2, based on interaction partners [138].  
Figure 7: VP16 Structure and Function 
A. Functional domains of the VP16 protein. B. Schematic of interaction of VP16 with
transcriptional activators and DNA, adapted from [139]
The VP16 activation domain is one of the most potent activation domains known due to 
its ability to interact with multiple transcriptional activators and chromatin modifiers (Figure 
7B). It is required for the recruitment TBP and RNA polymerase II to viral immediate early 
promoters and for maintaining immediate early promoters and reading frames in a relatively 
histone free state [140, 141]. In vitro studies using fusion proteins showed that the VP16 
activation domain recruits the RNA polymerase through direct interactions with the basal 
transcription factors TFIIA, TFIIB, TFIIF, TFIIH and several components of TFIID [142-
146].To further promote transcription, it recruits the mediator complex through direct 
interactions with two subunits, MED25 and MED17 [147, 148]. Recent ChIP studies have shown 
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that VP16 can interact with and recruit the histone deacetylases CBP and p300 and the SWI/SNF 
complex to immediate early promoters [140]. 
1.3.2 ICP4 
ICP4 is the master regulator of viral gene expression. The gene encoding ICP4 is present in the 
genome in duplicate in the inverted repeat regions of the virus. ICP4 is expressed early in 
infection and controls the expression of all other viral genes. The protein is 1294 amino acids 
long with a predicted molecular weight of 133kDa, however, due to extensive phosphorylation 
and ADP-ribosylation, its actual size is closer to 175kDa [149, 150]. There are several domains 
of ICP4 that are critical for its functioning. These domains are depicted in Figure 8A. ICP4 has a 
DNA binding domain that is required for its function as ICP4 must bind to DNA to recruit 
cellular transcription factors. It also has a multimerization domain which enables it to self 
interact and multimerize on DNA, increasing its binding affinity. ICP4 has both N-terminal and 
C-terminal activation domains.
ICP4 binds to the viral DNA through the recognition of the loose consensus sequence 
RTCGTCNNYNYSG where R is a purine, Y is a pyramidine, S is C or G, and N is any base 
[151]. There are strong ICP4 binding sites in the promoters of OrfP/L/ST, ICP4, and LAT which 
are required for their repression. However, the majority of the ICP4 binding sites on the genome 
are low affinity, and several have been shown to be dispensable for ICP4 transactivation [76]. 
ICP4 is able to bind to these weak sites through oligmerization on DNA which increases its 
overall affinity to the viral genome [77]. 
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Figure 8: ICP4 Structure and Function 
A. Domain schematic of ICP4 protein. B. Interactions of ICP4 with cellular transcription
machinery, adapted from [152].
Once bound to DNA, ICP4 promotes transcription through interactions of its N and C 
terminal activation domains with multiple cellular transcription factors, most notably TFIID and 
mediator. Different mutant viruses with deletions within the ICP4 coding regions have been used 
to tease apart the functions of the two activation domains. When the 520 C-terminal amino acids 
are deleted, the virus is able to activate early, but not late gene expression [153]. The C terminal 
domain of ICP4 has been shown to interact with TFIID through the TAF1 subunit [154]. When 
the N-terminal 30-210 amino acids are further deleted, the resultant ICP4 is unable to activate 
early or late genes or repress immediate early genes [155]. Deletion mutants where just the N 
terminal region is deleted have a similar phenotype, indicating that the N terminal domain is a 
true and required activation domain. The N-terminal 210 amino acids are required for interaction 
with TBP, TAF1, and Med1, a component of the mediator complex [79]. The structure of the N-
terminal regions is unstructured and elongated [156], which may enable it to form long range 
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contact with multiple transcription factors. While the C terminus is not a true activation domain, 
it may stabilize interactions of the N-terminal domain with transcription factors or enhance the 
binding of ICP4 to viral DNA to promote transcription. 
In addition to its interactions with TFIID and mediator, ICP4 has also been shown to 
interact with several chromatin remodeling complexes including SWI/SNF, NuRD, and Ino80 
throughout the lytic lifecycle [79]. While NuRD has been shown to be a repressor of gene 
expression, Ino80 and SWI/SNF can slide and eject nucleosomes to increase the accessibility of 
DNA, suggesting that ICP4 may function in maintaining an active chromatin state during active 
transcription.  
1.3.3 ICP0 
ICP0 has multiple functions in both lytic replication and reactivation that range from maintaining 
the viral chromatin in a euchromatic state permissive to transcription to disarming the cellular 
innate immune response. The gene encoding ICP0 is present in the genome twice and resides 
within the coding region on the latency associated transcript. ICP0 is a 775 amino acid long 
protein with several functional domains - most important of which is the ring finger domain 
which is required for its function. The domains of ICP0 are depicted below in Figure 9A. The 
ring finger domain has a characteristic fold seen in E3 ubiquitin ligases and is stabilized by 
coordination with 2 zinc atoms [157]. Mutations in the ring finger domain that abolish its activity 
create an identical phenotype to an ICP0 null mutant, indicating that this domain is necessary for 
its function. ICP0 is localized to the nucleus early in infection through a NLS around residue 500 
[158]. The NLS is essential for ICP0 function in both lytic replication and reactivation from 
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latency [159]. ICP0 also interacts with the cellular protein USP7, which removes ubiquitin 
modifications from ICP0, enhancing its stability [160]. 
Figure 9: ICP0 Structure and Function 
A. Domains of ICP0. B. Targets of ICP0 to counteract the host cell innate immune response on
several fronts, adapted from [161]
Interestingly, ICP0 null viruses can replicate to different efficiencies in different cell 
types. U2OS cells are permissive to infection to an ICP0 null virus, enabling the virus to 
replicate to the same efficiency as wild type virus [162], but replication in human diploid 
fibroblasts leads to a reduction of plaque formation of approximately 1000 fold [163]. However, 
this difference in replication efficiency only exists at low MOIs; as a larger MOI is used, the 
disparity in replication deficiency becomes smaller, indicating that ICP0 promotes viral 
replication for low numbers of incoming viral particles and that restrictive host cell factors can 
be titrated out with increasing concentrations of virus. Several innate suppressors of HSV 
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replication have been identified including ND10 bodies, chromatin modifiers, and innate 
immune signaling molecules – all of which are targeted for degradation or inactivated by ICP0. 
 ND10 bodies, also referred to as promyelocytic leukaemia protein (PML) bodies, are 
small nuclear substructures that are defined by the presence of the PML. PML is the primary 
component of ND10 bodies and serves as the scaffold for their assembly [164]. PML is SUMO 
modified, which aids in the recruitment of other proteins to the complex [165]. Over 50 proteins 
have been shown to associate with ND10, but not all are localized constitutively [166]. Some of 
these proteins, most notably PML, Sp100, hDaxx and ATRX have been shown to mediate 
repression of HSV genomes. Furthermore, siRNA knockdown of these proteins has been shown 
to partially restore replication of an ICP0 null mutant, but did not affect replication of wild type 
virus. Sp100 is an interferon inducible protein and major component of ND10. All isoforms of 
Sp100 have been shown to interact with the heterochromatin binding protein HP1, a protein that 
has also been shown to recruit histone methyltransferases that target H3K9 residues [167]. Some 
isoforms of Sp100 have also been directly linked to repression of immediate early gene 
expression [168]. ICP0 targets Sp100 through interactions with the SUMOlyated residues with 
its SIM domain for proteosomal degradation through its ring finger domain [169]. 
 In addition to Sp100, hDaxx and ATRX also are involved in the silencing of incoming 
HSV genomes. ATRX and hDaxx are constitutive components of ND10 and are localized 
through interactions of hDaxx with SUMO-modified PML [164]. These two proteins strongly 
interact and can be found in complex with several other chromatin modifying proteins. hDaxx 
has been shown the be a repressor of transcription and an interaction partner of histone 
deacetylase enzymes (HDACs) [113, 170]. hDaxx and ATRX have also been shown to restrict 
the replication of an ICP0 null HSV mutant, but not wild type virus indicating a role in 
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restricting viral replication. The interaction between these two proteins is required for this 
restrictive ability [112]. ICP0 has not been shown to destabilize these two proteins. However, it 
does alter their localization by inducing the degradation of the PML scaffold.  
In addition to ND10 components, ICP0 targets several cellular proteins that are 
responsible for activating the host cell innate immune response, including IFI16, NF-κβ, and toll 
like receptor (TLR) signaling adapter proteins. IFI16 is a nuclear DNA sensor that has been 
shown to induce an IFN-β response to HSV-1 infection. IFI16 has also been shown to induce 
heterochromatin deposition, promoting the methylation of H3K9 and demethylation of H3K4 
[171]. ICP0 promotes the relocalization of IFI16 to the cytoplasm and its subsequent proteosome 
mediated degradation. ICP0 also functions to sequester the downstream signaling protein IRF-3 
early in nuclear compartments during infection to block IFN-β expression [172].  
 ICP0 also targets signaling adapters for TLRs. HSV glycoproteins are recognized by 
TLR2 and TLR4 which both reside in the plasma membrane. Signaling through these receptors 
requires the adapter proteins MyD88 and Mal and results in the activation of transcription factors 
NF-κβ and AP1. ICP0 targets both of these adapter proteins for degradation by the proteosome in 
a ring finger dependent manner, resulting in a decreased inflammatory response [173]. ICP0 also 
directly targets NF-κβ to block immune activation. The NF-κβ transcription factor is composed 
of two fragments, p50 and p65. ICP0 targets p50 for proteosomal degradation, preventing the 
nuclear translocation of p65 and thus blocking NF-κβ signaling [174].  
 ICP0 also blocks the deposition of repressive chromatin on the viral genome through 
interactions with HDACs. HDACs remove activating acetylation marks from chromatin, 
reducing transcription. ICP0 has been shown to directly interact with the N terminal region of 
class 2 HDACs. ICP0 does not appear to induce degradation of these proteins; rather it changes 
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their localization in the nucleus of infected cells and counteracts HDAC mediated transcriptional 
repression [175]. ICP0 also targets the CoREST/REST/HDAC1 repressor complex early in 
infection. ICP0 has a domain of approximately 76 amino acids that is homologous to the 80 C-
terminal amino acids of CoREST. ICP0 induces the dissociation of HDAC1 from the complex 
[176].  
Furthermore, ICP0 deactivates the DNA damage response, which has been recently 
shown to activate immune signaling in response to DNA viruses [177]. The DNA damage 
signaling cascade is mediated by three kinases, DNA dependent protein kinase (DNA-PK), 
ataxia telangectasia mutated (ATM) kinase, and ATM and Rad3 related (ATR) kinase. Infection 
with HSV leads to the activation of the ATM pathway [178]. ICP0 directs the proteosomal 
degradation of DNA-PK and both of the downstream signaling proteins of the ATM pathway, 
RNF8 and RNF 168 to block activation of this response [179, 180]. 
Through disarming multiple facets of the host cell innate immune response to viral 
infection, ICP0 promotes viral replication, especially when there is a low number of incoming 
virions. A summary of ICP0 targets is depicted in Figure 9B. ICP0 also functions to remove 
chromatin from the viral genome during reactivation, but that will be discussed in a later section. 
1.4. LATENCY 
1.4.1. Viral Entry into the Ganglia 
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Unlike infection of epithelial cells where the viral capsid and associated tegument proteins travel 
a short distance from the cell membrane to the nucleus, when the virus enters neurons through 
the axon termini, it must travel a much greater distance up the length of the axon to reach the 
soma and nucleus. This distance differential may affect the ability of the virus to enter productive 
infection. In one study, infection of neurons at the soma yielded a productive infection, where as 
infection at the axon termini largely yielded a quiescent latency-like state. However, the genome 
remained responsive to VP16 transactivation through delivery by helper virus, indicating that the 
viral genome transited to the nucleus, but failed to initiate lytic replication and virus production 
[181]. The inability of virus to enter lytic replication can be attributed to a loss of VP16 from the 
viral tegument as the viral particle travels up the axon, through the soma and into the nucleus. A 
study using gold labeled VP16 showed that as viral particles moved through the axon, VP16 was 
lost from the tegument and was dispersed in the axon and soma cytoplasm [182]. Furthermore, 
unlike in epithelial cells, the HCF protein which is required for VP16 function is localized to the 
cytoplasm [183]. The loss of VP16 from viral capsids during entry coupled with cytoplasmic 
localization of HCF may account for the less permissive state of neurons and the propensity for 
the virus to form a latent reservoir.  
Furthermore, recent evidence has shown that a neuron specific micro RNA (miRNA), 
miR-138, targets the ICP0 transcript at two distinct sites, resulting in a decrease in ICP0 
expression and lytic gene transcription. Deletion of these target sites in ICP0 resulted in an 
increase in viral gene expression and replication and viral spread in the ganglia leading to 
encephalitic infections in mice [184]. The neuron specific expression of this miRNA likely 
reduces lytic gene expression through decreasing ICP0 expression, limiting the initial round of 
lytic replication in the ganglia.  
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Latency is established in approximately 5-20% of the sensory neurons in the ganglia and 
the large majority of these neurons express the surface antigen recognized by the A5 antibody 
[185]. Specific elements in the LAT region may play a role in determining cell tropism for the 
establishment of latency [186]. During latency, the viral genome persists in an endless form, 
probably as a circular episome in the nuclei of infected cells and is repressed by cellular 
heterochromatin. The large majority of the genome is transcriptionally silent, except for the 
latency associated transcript and is correlated to this epigenetic state of local chromatin, 
discussed in the next section.  
1.4.2. Chromatin Dynamics during Latency 
Both euchromatic and heterochromatic marks have been identified on the viral genome 
during latency. Euchromatic modifications, including acetylated H3 at positions 9 and 14 as 
well as trimethylated H3K4, have been detected specifically within the LAT locus, partially 
explaining its high level of transcription during latency [187]. However, the LAT locus also has 
been found to have markers of heterochromatin, including trimethylated H3K9 and 
H3K27 and incorporation of the repressive histone variant macroH2A into nucleosomes [188]. 
This suggests that not all latent viral genomes are equal in their chromatin modification and 
may explain why only 1/3 of latently infected neurons express LAT.  
While the LAT locus can be enriched in both euchromatin and heterochromatin, lytic 
genes have been shown to be exclusively associated with repressive heterochromatin during 
latent infection. These genes bear marks of both constitutive and facultative heterochromatin. 
Constitutive heterochromatin exists in tightly condensed 30nm fibers and is often considered an 
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irreversible form of heterochromatin as it cannot be reverted back to euchromatin. The other 
form of heterochromatin, facultative heterochromatin, is a more reversible form of chromatin and 
exists in multiple states of compaction. These two forms can be distinguished from each other 
based on the histone modifications made by different sets of chromatin modifying enzymes.  
 Constitutive heterochromatin is characterized by the di and trimethylation of H3K9. 
Studies have shown that H3K9 methylation increases in abundance on the viral genome in the 
trigeminal ganglia of mice as latency is established in vivo [189]. Furthermore, constitutive 
heterochromatin deposition on the genome has been demonstrated in quiescent models of 
latency. HSV viruses in which immediate early genes have been deleted enter a non-productive 
persistent infection in primary human fibroblast cells [190]. The genomes of these viruses 
become enriched in repressive chromatin marks including trimethylated H3K9 and 
heterochromatin protein 1 (HP1) [191]. HP1has been shown to drive condensation of chromatin 
through dimer formation bridging two nucleosomes [192]. HP1 also interacts with and recruits 
the H3K9 methyltransferase Suv39h1 to promote the spread of heterochromatin [193]. The 
location of the genome during latency may promote the deposition of constitutive 
heterochromatin. The viral genome is localized to ND10 bodies and centromeres of 
chromosomes during latent infection [194]. HP1 also interacts with the ND10 component Sp100 
and is also localized to centromeric heterochromatin, possibly linking constitutive 
heterochromatin deposition to localization at these two areas [167, 195].  
 Facultative heterochromatin is characterized by the presence of trimethylated H3K27 and 
the incorporation of the histone variant macroH2A. The trimethylation of H3K27 is mediated by 
polycomb repressive complex 2 (PRC2) and the maintenance of this modification as well as 
further compaction of chromatin is maintained by polycomb repressive complex 1 (PRC1). Both 
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trimethylated H3K27 and macroH2a have been observed on the genome during latency [196]. 
Additionally Suz12, a component of PRC2, has been shown to be bound to the viral genome 
during the establishment of latency, implicating PRC2 in the deposition of facultative 
heterochromatin [118]. Furthermore, Bmi1, a component of PRC1, occupies the viral genome 
during latency, suggesting PRC1 maintains facultative heterochromatin during latency [196]. 
Since there are separate regions of euchromatin and heterochromatin during latency, 
boundaries are necessary to prevent unwanted spread of heterochromatin into areas of 
euchromatin and vice versa. Insulator elements are DNA sequences that protect genes from 
signals emanating from their surrounding environment. Two main classes of insulator elements 
have been identified: enhancer blockers and barriers [197]. Enhancer blockers are located 
between enhancers and promoters and prohibit the action of an enhancer on a nearby promoter, 
enabling the enhancer to activate specific promoters without off target effects. The second class 
of insulator, a barrier, separates regions of different chromatin structure, reviewed in [198]. The 
CTCF protein was the first protein to be demonstrated to bind insulator elements in vertebrate 
genomes and function as an enhancer blocker/barrier [199]. Computational analysis of the 
human genome has identified nearly 15,000 potential CTCF binding sites, of which 13,804 have 
been confirmed through chromatin immunoprecipitation-microarray experiments [200, 201]. 
Nucleosomes near CTCF binding sites are well positioned and are modified with trimethylated 
H3K27 or acetylated H2AK5, depending on which side of the element the nucleosomes falls on 
[202]. Thus, CTCF plays an important role in maintaining chromatin by serving as a boundary 
between euchromatin and facultative heterochromatin. 
Seven clusters of CTCF elements have been identified in the HSV-1 genome and have 
been shown to be occupied by CTCF protein during latent infection. One cluster lies upstream of 
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the LAT promoter near the unique long-repeat short junction. A second cluster, CTRL2, is 
located within the LAT intron downstream from the LAT enhancer and upstream of ICP0. Other 
clusters were found to be located within the “a” sequences, the repeat short region, and in the 
unique short region. The CTRL2 insulator element has been shown to function as an enhancer 
blocker and blocks the effects of the LAT enhancer on the ICP0 promoter [203]. Other labs have 
confirmed this finding and have also shown that CTRL2 can also function as a barrier when 
inserted into the Drosophila genome [204]. Together, these results indicate that insulator 
elements function to both separate areas of euchromatin and heterochromatin during latency and 
also block activation of ICP0 by the LAT promoter.  
The latency associated transcript has been implicated in the regulation of chromatin 
modification during latent infection, but the effect differs between viral strains. Deletion of the 
LAT promoter or sequences within the transcript led to decreased H3K27 methylation in the 
KOS strain [188]. The LAT transcript may function to target PRC2 to lytic genes during latency 
through interaction with EZH2. Non-coding RNAs such as Xist have been shown to mediate 
targeting of PRC2 to genes through interaction of the EZH2 subunit with RNA [205].  
However, similar deletions in the strain 17 led to an increase in H3K27 methylation 
[196]. This discrepancy warrants further investigation to determine if the difference is due to the 
site of latency, as Cliffe studied the TG [188] and Kwiatkowski [196] studied the DRG as latent 
models, or the specific strain, since these viruses do differ in their pathogenicity.  
1.4.3. Gene Expression and the Latency Associated Transcript 
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During latency, the main transcript expressed from the virus is the latency associated transcript 
(LAT) while the expression of other genes is heavily attenuated. The LAT locus is located within 
the inverted repeat long region and this is present in the genome twice. It runs antiparallel to 
ICP0, γ34.5 and ICP4. The LAT is expressed as a 8.5kb polyadenylated transcript, consisting of 
two exons and one intron, and can be spliced to form a stable 2kb intron. The 2kb intron can be 
further spliced to 1.5kb in some neurons [206]. The predominant form of the LAT transcript is 
the 2kb intron since it is incredibly stable, with a half life of 24 hours due to its lariat structure 
[207]. The LAT transcript has been shown to have multiple functions in latency including 
repressing lytic gene expression through its encoded miRNAs, preventing cell apoptosis, and 
establishing and reactivating from latency.  
 To date, 17 mature microRNAs originating from the virus have been identified in 
infected cells. Of these 17 microRNAs, only 9 of them have been shown to be loaded into the 
RISC complex, the complex responsible for targeting miRNAs to their respective targets. These 
microRNAs include miR-H1-H8 and miR-H11 [208]. Many of these functional microRNAs are 
located within the LAT region, suggesting that LAT functions as a microRNA precursor, 
reviewed in [209]. MicroRNAs originating from LAT include H1-5, H7, H8, H14 and H15. 
Many of these LAT encoded microRNAs have been shown to repress lytic gene expression to 
maintain latency. MiR-H2 has been shown to downregulate ICP0 expression in cell culture, but 
does not target other immediately early genes [210, 211]. Furthermore, in vivo studies in mice 
showed that when this miRNA was knocked out, neurovirulence and the frequency of 
reactivation was enhanced [212]. These results suggest that miR-H2 functions to decrease 
neurovirulence to promote survival of the host and maintain latency through targeting ICP0.  
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1.5. REACTIVATION 
HSV can reactivate from latency following stress to the host. Common stressors include UV 
exposure, psychological stress, and immune suppression [213]. It has also been known for over 
100 years that severing the trigeminal nerve leads to reactivation of HSV [214]. Until recently 
however, the molecular mechanism underlying this observation was unknown. Reactivation 
induced by cutting the trigeminal nerve or explanting the ganglia proceeds via a similar 
mechanism – disruption of the NGF signaling pathway which maintains latency. NGF signals 
through the TrkA receptor and can activate multiple pathways. However, only the PI3-K 
signaling pathway was shown to be necessary to maintain latency, as inhibitors targeting this 
pathway but not others resulted in reactivation of virus. Even transient disruption of this 
signaling pathway was sufficient to induce reactivation. Active PI3-K recruits PDK1 to the 
plasma membrane, leading to its phosphorylation and the phosphorylation of Akt. The duration 
of signaling through Akt was found to be directly correlated to maintenance of latency, with 
NGF being the most potent activator of long lasting activation of the pathway. However, the 
downstream targets of Akt were not identified in this study [215]. The cellular mTOR kinase is a 
target of the PI3-K Akt pathway and has been implicated in the maintenance of latency. 
Inhibition of this protein or raptor, its regulatory subunit responsible for complex assembly and 
substrate specificity, led to reactivation of latent virus. mTOR functions to inhibit 4E-BP, a 
translational repressor, suggesting that proteins whose translation is impeded by 4E-BP may be 
involved in controlling latency [216]. Additional studies are needed to identify the proteins 
targeted by this protein involved in the reactivation pathway.  
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 Disabling the NGF signaling pathway through inhibition of PI3-K leads to a biphasic 
transcription pattern during reactivation. The first phase occurs between 0 and 20 hours 
following the reactivation stimulus and is marked by a transient induction of global gene 
expression. During this phase, genes from all kinetic classes are expressed independent of 
protein synthesis and DNA replication, as gene expression was similar with and without 
cyclohexamide or PAA treatment. Coincident with this gene expression is the cytoplasmic 
accumulation of VP16 protein. Between 20 and 25 hours, gene expression declines and is 
followed by a second phase of expression. The second phase begins with a relocalization of 
VP16 and HCF to the nucleus, leading to the formation of the VP16 Oct-1 HCF transcription 
complex which stimulates the expression of immediate early genes. Interestingly, inhibition of 
the NGF signaling pathway induces the nuclear translocation of HCF which resides in the 
cytoplasm under normal conditions. During the second phase of transcription, gene expression is 
dependent on DNA replication, indicating this pattern is more similar to the lytic cascade. It is 
also during this phase when infectious virus is produced [217].  
Additional studies have also confirmed this observation. Early following reactivation 
stimulus, lytic gene expression is induced independent of protein expression. Concurrently, 
expression of the LAT and its associated miRNAs also declined. The accumulation of viral lytic 
transcripts and continued expression of LAT was mutually exclusive. Also, unlike the lytic 
transcripts, the decrease in LAT expression is dependent on protein expression, suggesting that a 
viral protein may be involved in the degradation of the LAT transcript during reactivation [218]. 
Since the burst of transcription during reactivation was independent of protein production, it is 
likely mediated my existing cellular proteins, possibly including chromatin remodeling 
complexes.  
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During reactivation from latency, the viral genome must transition from a 
heterochromatic to euchromatic state to enable lytic viral transcription to resume. Several 
cellular chromatin remodeling complexes have been implicated in removal of repressive 
chromatin during reactivation. In an in vitro model of latency using anti NGF antibodies to 
induce reactivation, chemical inhibition of the two H3K27 demethylases JMJD3 and UTX 
resulted in decreased expression from various kinetic classes of viral transcripts along with a 
decrease in the production of infectious virus. This decrease in transcription and viral titer was 
correlated to high levels of trimethylated H3K27 on the viral genome, indicating that removal of 
facultative heterochromatin from the viral genome by JMJD3 and UTX was required for 
maximal reactivation [219]. Furthermore, in in vivo models using explant induced reactivation, 
specific inhibition of LSD1 led to a significant reduction in viral yield compared to mock treated 
controls, indicating that LSD1 is also important for reactivation of the virus [220]. These two 
studies taken together suggest a role of cellular chromatin remodeling complexes in removing 
repressive chromatin from the viral genome to enable reactivation of the virus.  
 In addition to changes in histone modification, there are also changes in CTCF occupancy 
on the genome during reactivation. As discussed in the previous section, CTCF elements are 
located around the LAT, ICP0, and ICP4 genes. During latency, these sites are occupied by 
CTCF and serve as enhancer blockers, preventing the activation of lytic genes by the LAT 
enhancer. Following a reactivation stimulus, CTCF occupancy at these sites rapidly decreased, 
with a 50% reduction within the first hour. Furthermore, the loss of CTCF from some sites 
during reactivation was dependent on IE gene expression, indicating that IE genes may 
contribute to the loss of CTCF [221]. The disruption of these boundaries may enable activation 
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of ICP0 by the LAT enhancer or the spread of euchromatin from the LAT region to other areas 
of the genome.  
Additional studies have focused on determining which viral activators are sufficient to 
induce reactivation in quiescent models of latency. In quiescent models of latency, a virus 
lacking immediate early genes is repressed in cell culture and acquires chromatin modifications 
similar to in vivo latency [191]. Studies using a B-galactosidase reporter virus showed that 
expression of ICP0, but not an ICP0 mutant lacking the ring finger domain, was sufficient to 
induce expression of the reporter gene [159]. Further studies showed that provision of ICP0 to 
quiescently infected cells leads to the derepression of silencing chromatin, including removal of 
H3 and H4, reduction in H3K9 methylation, and increases in histone acetylation [222]. Later 
studies showed that the ring finger domain of ICP0 was required for the ability to induce changes 
in chromatin [223]. 
 However, cellular stress has been shown to be sufficient to reactivate quiescent genomes 
in the absence of ICP0. Treatment of cells with either sodium arsenite - a general enzyme 
inhibitor - or gramicidin D - a pore forming toxin that renders the membrane permeable to 
monovalent cations - led to reactivation, measured by the expression of a reporter gene. 
Furthermore, toxin treatment induced the expression of cell stress proteins and led to a reduction 
in PML foci, suggesting a link between cellular stress and PML mediated repression of viral 
genomes, as viral genomes are localized to PML bodies during quiescence [111, 224]. These 
results are consistent with another study that showed cellular stress enhanced the replication of 
ICP0 null viruses in cell culture [225].  
Overall, there are multiple factors that contribute to reactivation from latency including 
NGF signaling, cellular stress, chromatin remodelers, and viral factors. As there are many 
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mechanisms to induce latency, the exact proteins required for reactivation may change based on 
the reactivation stimulus.  
1.6. FORMS OF CHROMATIN 
1.6.1 Nucleosomes 
The basic building blocks of chromatin are nucleosomes, which consist of the two copies of each 
of the core histone proteins – H3, H4, H2A and H2B - DNA, and sometimes the linker histone 
H1. Histone proteins are relatively conserved from yeast to higher mammals [226]. During 
formation of a nucleosome, 146-147 base pairs of DNA are wrapped around the histone octamer 
[227]. The nucleosome unit is a disc-like structure 5nm tall and 11nm wide [228]. Histone 
proteins are small, only 11-15kDa, and are basic, enabling association with the negatively 
charged DNA. Each core histone protein, although varied in amino acid sequence, is composed 
of two domains, a globular domain rich in alpha helices which serves as the site of histone-
histone and histone-DNA interactions, and an unstructured tail domain which can be modified by 
various chromatin modifying enzymes to augment the structure of chromatin [229].  
The histone proteins interact to from dimers, tetramers and finally octamers. The histone 
folds in the globular domain mediate the formation of heterodimers of H3-H4 and H2A-H2B. 
H3-H4 dimers then interact to form stable tetramers through interactions along the face of H3. 
Once the tetramer has formed, H2A-H2B dimers associate through interactions between the 
faces of H2B and H4. However, the interaction between H2B and H4 is much weaker than the 
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interaction between H3-H3 in tetramers, so the full histone octamer is not formed unless in 
contact with DNA or in high salt concentration. [230]. Nucleosomes evenly spaced on a DNA 
template make up the 11nm fiber [231]. The linker histone H1 binds to the histone octamer to 
protect DNA between neighboring nucleosomes and aids in the formation of higher order 
chromatin structures by compacting the chromatin into 30nm fibers [232].  
There are several forms of chromatin including euchromatin, constitutive 
heterochromatin and facultative heterochromatin. These forms differ in their accessibility to 
transcription factors and in the modifications present on their histone tails, deposited by different 
chromatin modifying enzymes. The histone tail modifications also serve as docking sites for 
different proteins that may further alter the chromatin structure. A general overview of the 
structure of these three forms of chromatin is presented below in Figure 10. Each form of 
chromatin will be discussed in greater detail in the following sections. 
Figure 10: Forms of Chromatin 
A. Euchromatin is rich in histone acetylation and H3K4 methylation. The acetylation neutralizes 
the positive charge of the lysine residues, decreasing the affinity of DNA for the histone proteins. 
For this reason, euchromatin is more open and permissive to transcription. B. Constitutive 
heterochromatin is characterized by densely packed nucleosomes rich in H3K9 methylation. Due 
to the compact structure, regions of the genome occupied by constitutive heterochromatin are not 
expressed. HP1 recognizes and is recruited to H3K9 trimethylation and aids in the further 
compaction of chromatin and spread of H3K9 methylation through recruitment of the 
methyltransferase Suv39h1. C. Facultative heterochromatin is a silencing form of chromatin, but 
can transition back to euchromatin. It is enriched in H3K27 trimethylation, deposited by PRC2 
and H2AK119 ubiquitination, deposited by PRC1.
1.6.2. Euchromatin 
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Euchromatin has a looser, more unfolded and less structured conformation than heterochromatin 
to allow access to transcription factors access to DNA, making it the transcriptionally active 
form of chromatin. For this reason, actively transcribed genes tend to be enriched in 
euchromatin. Euchromatin is characterized by wide spread histone acetylation and specific 
activating methylation marks. Acetylation of H3 at positions K9 and K14 along with 
trimethylated H3K4 are enriched at the transcription initiation site of eukaryotic genes, but these 
modification are greatly decreased downstream of the transcription start site [233]. Additional 
studies have also shown that the acetylation of H2AK9, H2BK5, H3K18, H3K36 and H4K91 are 
also localized to transcription start sites, while acetylation of H2BK12, H2BK20, H2BK120, 
H3K4, H4K5, H4K8, H4K12, and H4K16 are found both in the promoter and transcribed regions 
of active genes [234]. Acetylation of histones has been shown to enhance the binding of 
transcription factors to nucleosomal DNA in vitro [235, 236]. In vivo studies have been less 
fruitful in establishing a level of acetylation required for efficient transcription factor binding 
since there are redundancies in acetyltransferase function and knockdown of several factors is 
detrimental to cells.  
The acetylation of histone tails is the main determinant of compaction, as the addition of 
an acetyl group to lysine neutralizes the positive charge and disrupts electrostatic interactions 
between the histones and negatively charged backbone of DNA, but does not directly lead to 
unfolding of individual nucleosomes [237, 238]. There are small increases in temporary 
unwrapping of DNA near the edges of hyperacetylated nucleosomes [239]. The main change in 
chromatin upon histone acetylation is the formation of higher order structures. Acetylation of 
histones leads to the adoption of an extended chromatin structure [240]. One possible mechanism 
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for this change is the weakening of internucleosomal contacts. H4 makes extensive contacts with 
the H2A-H2B dimer of neighboring nucleosomes, and the amino acids of H4 that mediate this 
interaction are subject to acetylation [241]. Specifically, acetylation of H4K16 inhibits the 
formation of the compacted 30nm fiber [242]. However, histone acetylation alone is not 
sufficient to overcome nucleosome blockage during transcription elongation, suggesting 
additional factors are involved [243].  
In addition to preventing the formation of higher order chromatin structure, histone 
acetylation can also enhance the function chromatin remodelers, including the Swi/Snf complex. 
The Swi/Snf complex is a chromatin modifying ATPase that uses energy from ATP hydrolysis to 
disrupt and slide nucleosomes on DNA [244]. This complex contains a bromodomain which 
specifies binding to acetylated histones [245]. Studies have shown that enhanced action of 
chromatin remodelers on acetylated templates is mainly due to an increase in affinity, not 
enhanced catalytic function [246]. 
The concerted action of acetyl transferases along with the recruitment and action of 
histone remodeling complexes maintains euchromatin in a loose structure that is permissive to 
gene expression. 
1.6.3. Constitutive Heterochromatin 
Constitutive heterochromatin is localized mainly to telomeres and pericentromeric regions 
of chromosomes, which are usually gene poor areas consisting of tandem repeats or satellites 
that vary in size from 5 to a few hundred base pairs [247]. This form of chromatin is very 
densely packed and transcriptionally inert. The most prominent histone modification is the 
trimethylation 
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of H3K9, which is deposited in a sequential manner by several histone methyl transferases. The 
first step is the monomethylation of H3K9 which is mediated by three enzymes Prdm3, Prdm16, 
and SETBD1 and may occur prior to the deposition of histones onto DNA [248, 249]. The two 
isoforms of Suv39h1/2 mediate the di- and trimethylation of H3K9 specifically at 
pericentromeric sites, as knock down of these two proteins leads to a decrease in H3K9 
methylation at pericentromeric regions, but not other locations on chromosomes, suggesting a 
specific targeting mechanism [250]. Studies in Schizosaccharomyces pombe have implicated 
RNAi in directing H3K9 methylation [251], but how Suv39h proteins are targeted initially to 
chromatin in mammals is not clear, but the mechanism for their maintenance on constitutive 
heterochromatin is mediated by interactions between their chromodomain and H3K9me3. 
Trimethylated H3K9 also serves as a docking site for heterochromatin protein 1 (HP1), an 
interaction partner of Suv39h [252]. HP1 can bind to two separate H3K9me3 residues and has 
the ability to dimerize, linking to nucleosomes occupying different loci to promote compaction 
of chromatin [253]. 
Another hallmark of constitutive heterochromatin is the di- or trimethylation of H4K20, 
however, the function of this specific modification in silencing is unclear. The trimethylation of 
H3K9 is a prerequisite for this modification, as HP1 has been shown to interact with and recruit 
Suv420h, the enzyme responsible for this modification. Suv420h has been shown to be involved 
in the binding of cohesins to heterochromatin, suggesting a role in sister-chromatid cohesion and 
chromosome segregation during mitosis [254, 255]. Additional modifications including H3K27 
monomethylation and H3K64 trimethylation have been observed on constitutive 
heterochromatin, but their function is not yet clear. The methylases PRC2 and G9a have been 
suggested to methylate H3K27, but have not been proven.  
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Differential incorporation of histone variants has also been observed at sites of 
constitutive heterochromatin. The swi/snf chromatin remodeler ATRX has been found to be 
enriched at pericentromeric heterochromatin and to recruit Daxx in a cell cycle dependent 
manner [256, 257]. These two proteins are involved in the deposition of histone variant H3.3 in 
repetitive regions. This incorporation may serve to help transcription, which is correlated to the 
recruitment of H1 and is critical for the formation of heterochromatin in developing mice [258]. 
The other histone variant is H2A.Z [259], which contains a unique acidic patch located on its 
surface. This region binds to the tail of H4 with greater affinity and likely contributes to 
enhanced chromatin folding. Furthermore, HP1 is recruited to H2A.Z containing nucleosomes 
and stabilizes the interaction of H2A.Z with H4 of neighboring nucleosomes to further promote 
the packing of chromatin into dense fibers. HP1 has a 2.5 fold higher affinity for H2A.Z than 
H2A suggesting that different heterochromatic regions containing exclusively one variant over 
the other may differ in their structure [260]. H1 and its variant H5 are enriched and function to 
promote higher order structures by clamping DNA fibers to nucleosomes. H5 tends to be more 
enriched with highly compacted and repressed chromatin [261]. 
Through the trimethylation of H3K9 and recruitment of HP1, constitutive 
heterochromatin adopts a highly condensed state which is refractory to transcription. 
1.6.4. Facultative Heterochromatin 
Like constitutive heterochromatin, facultative heterochromatin is also transcriptionally silent, 
but retains the ability to transition back to euchromatin to allow transcription in different 
contexts. This transition can occur during: i) temporally regulated processes such as 
development or cell 
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division, ii) changes in localization in the nucleus, and iii) expression of specific genes. The 
mechanisms regulating this transition are still under investigation, but include changes in histone 
components, chromatin modification, action of cellular proteins, and nuclear localization [262]. 
For this reason, facultative heterochromatin is differentially localized in different cell types, 
depending on which genes must be silenced at a particular time. This form of chromatin is also 
present in the inactive X chromosome. 
Facultative heterochromatin can adopt a wide variety of structures, ranging from the 
confined compaction of the 11nm fiber to the condensed 30nm fiber and different forms of 
higher order chromatin structure. The most common model to study facultative heterochromatin 
structure and function is the inactive X chromosome. Studies of this chromosome have shown 
the heterochromatin has a unique ultra structure - a porous structure containing chromatin 
substructures with intervening spaces ranging in length from 30-400nm. The level of compaction 
is between that of constitutive heterochromatin and euchromatin. Regions of facultative 
heterochromatin are localized to the nuclear periphery in structures known as Barr bodies, which 
is correlated to repression of transcription [263, 264].  
 X inactivation has also shown sequential changes in histone modifications and histone 
variant incorporation into nucleosomes. These changes are diagramed in Figure 11. The Xist 
RNA has been shown to direct the inactivation of the X chromosome. The earliest changes in the 
formation of facultative heterochromatin include the loss of euchromatin markers including 
H3K9 acetylation and H3K4 di- and trimethylation followed quickly by H4 hypoacetylation 
[265, 266]. The exact mechanism underlying the loss of these modifications has not yet been 
clearly elucidated. Following the loss of euchromatic marks, repressive marks are deposited 
including H3K27 trimethylation, H3K9 dimethylation, H4K20 methylation, and H2A 
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ubiquitination [267, 268]. However, these modifications are not consistent throughout the 
inactivated x chromosomes as there are differences in their distribution [269].  
 
Figure 11: Formation of Facultative Heterochromatin  
Summary of the changes in histone modifications during the transition of euchromatin to 
facultative heterochromatin, adapted from [270] 
 
 Many of the enzymes responsible for these modifications have been identified, or likely 
candidates are suspected. The methyltransferase responsible for H4K20 mono-methylation is 
unclear, but PR-Set7 is a strong candidate [271]. G9a is also suspected to be the H3K9 
methyltransferase, but this has not been experimentally proven. However, the proteins 
responsible for H3K27 methylation and H2A ubiquitination have been identified as the two 
polycomb complexes. PRC2 is recruited to the DNA through Xist RNA mediated targeting and 
methylates H3K27. These methylation marks serve as a docking site for PRC1 which 
ubiquitinates H2A at lysine 119. These two complexes are reviewed in greater detail in later 
sections.  
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The histone variant macro H2A is recruited to facultative heterochromatin through 
interactions with the Xist RNA [272]. The properties of nucleosomes formed in the presence of 
macro H2A differ from those of the canonical nucleosome. Histone octamers containing macro 
H2A are more stable than canonical nucleosomes in the absence of DNA due to more 
internucleosomal contacts and are resistant to chaperone assisted H2A-H2B dimer exchange 
[273, 274], making them more repressive.  
1.7. CHROMATIN REMODELING COMPLEXES 
As there are many chromatin remodeling and modifying complexes, this section will focus 
mainly on the complexes that have been shown to be or hypothesized to be responsible for 
modulating chromatin dynamics on the HSV genome during lytic and latent infection. 
1.7.1. Histone Acetyltransferase Complexes 
CBP/p300 
CBP and its paralog p300 have overlapping function as they often play similar roles in the cell, 
but sometimes have distinct functions. Since their functionality is so similar, they are often 
collectively referred to as CBP/p300 [275]. These proteins are important transcription 
coactivators that function to both recruit additional coactivators and remodel chromatin. They 
share similar domains, referred to as transactivation domains, which mediate their interactions 
with transcription factors, components of the general transcription machinery, and other 
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coactivators. The presence of 4 TADs enables CPB/p300 to simultaneously interact with 
multiple proteins. CBP/p300 also has a HAT domain that enables it to acetylate both histones 
and other proteins, as well as a bromodomain which mediates its interactions with acetylated 
histones [276]. Figure 12 shows some of the interaction partners of CBP/p300 and how it can 
bridge transcription factors to the general transcription machinery. 
Figure 12: CBP/p300 Interactions 
Functions of the CBP/p300 complex include bridging transcription factors (TFs) to the general 
transcription machinery and recruiting the coactivators PCAF and GCN5. CBP/p300 also has its 
own acetyltransferase activity and can acetylate both histones and transcription factors to 
augment their function, adapted from [277]. 
CBP/p300 has been shown to be part of the RNA PolII holoenzyme, and the association 
is enhanced by the presence of RNA helicase A [278, 279]. Depletion of CBP/300 from the 
holoenzyme decreased its association with TFIIB and TBP, indicating that it may provide 
binding sites for these proteins [280]. CBP/p300 may also form transient interactions with TFIIE 
and TFIIF to mediate their acetylation [281]. It also interacts with and recruits the HATs PCAF 
and GCN5, which are more diverse in their structure and substrate specificity. These two 
proteins often synergistically act with CBP/p300.  
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In addition to being a protein interaction hub, CBP/p300 possesses its own intrinsic HAT 
enzymatic activity and will acetylate histones in its general vicinity [282]. It will acetylate all 
possible residues on histones 2A and 2B and will specifically acetylate K14, K18 and K27 on H3 
as well as K5 and K8 of histone 4 [283, 284]. It also targets H3K56, but acetylation of this 
residue is associated with DNA compaction rather than relaxation of chromatin structure [285]. 
CBP/p300 also acetylates non-histone substrates such as transcription factors to either enhance or 
decrease their activity. The effect of acetylation varies between transcription factors and is 
reviewed in [277]. 
CLOCK 
The CLOCK protein is most well known as the master regulator of circadian rhythms, but it has 
also been shown to be involved in the HSV lifecycle. During lytic infection, CLOCK is recruited 
to ND10 bodies where incoming genomes localize and facilitates viral transcription through 
modification of viral chromatin [131]. ICP0 has been shown to directly interact with BMAL1, an 
interaction partner of CLOCK, and form a transcriptionally active complex, capable of 
enhancing expression from a reporter gene [286]. HSV infection has been shown to stabilize the 
CLOCK protein, as it usually undergoes rapid turnover in a proteosome dependent manner [131]. 
The CLOCK protein has intrinsic acetyl transferase activity which is further enhanced by the 
presence of its interaction partner BMAL1. This protein heterodimer acetylates histone 3 [287]. 
MLL1, a H3K4 histone methyltransferase, also associates with CLOCK and is recruited to target 
genes in a circadian dependent manner [288].  
1.7.2. Histone deacetylase complexes 
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Histone deacetylases 1 and 2 (HDAC1 and HDAC2) are components of multiple deacetylase 
complexes including the CoREST and NuRD. These two proteins cannot bind to DNA 
independently and likely require interacting partners for catalytic activity [289]. CoREST has 
been implicated in silencing incoming HSV genomes by removing activating acetyl and methyl 
marks [120]. NuRD has not been directly implicated in the HSV lifecycle, but has been shown to 
co-purify with ICP4 during immunoprecipitation experiments in lytic infection [79]. A schematic 
showing the protein components of each of these complexes is depicted below in Figure 13. Both 
of these complexes will be discussed in greater detail.  
 
 
Figure 13: HDAC Complexes 
Protein components of the two HDAC1/2 containing complexes NuRD and CoREST, adapted 
from [290] 
 
NuRD Complex 
The NuRD complex possesses both deacetylase activity and ATP dependent nucleosome 
remodeling activity. The Mi2α/β proteins, also known as CHD3/CHD4, are the ATPase subunits 
and can function as ATP dependent chromatin remodelers independent of their association with 
the NuRD complex, but less efficiently [291]. These proteins also have PHD chromodomains 
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that mediate their interaction with histone H3 tails. Furthermore, the modification of H3 tails 
affects the affinity of the PHD domain; trimethylated H3K9 increases the affinity, while 
trimethylated H3K4 abolishes it [292, 293]. The chromodomains have also been shown to 
modulate the ATPase activity by steric hindrance, either by blocking the DNA binding domain 
or ATP binding domain, providing a mechanism for control. Structural rearrangements in CHD4 
enable catalytic activity [294]. CHD3/4 is also in direct contact with HDAC1 and likely serves as 
a scaffold for complex assembly. 
The MBD2 and 3 proteins are members of the methyl cytosine-guanine-binding domain 
family and bind to methylated DNA. MBD2 strongly associates with methylated DNA, whereas 
the affinity of MDB3 is much lower [295]. MBD2/3 can also mediate the targeting of the NuRD 
complex to different subsets of genes [289]. RBBP4 and 7 are WD repeat histone chaperone 
proteins that bind to histone H4. When bound to RBBP4/7, histone H4 undergoes unfolding to be 
accessible, which may be essential for ATP dependent remodeling [296]. The MTA proteins 
have been shown to interact directly with transcriptional repressors and the estrogen receptor to 
mediate gene silencing [297]. The GATA2 subunit is involved in binding to unmodified histone 
tails [298].  
REST CoREST Complex 
The REST-CoREST complex has both deacetylase activity mediated by HDACs1 and 2, as well 
as demethylase activity driven by the histone demethylase LSD1. This complex is distinctly 
different from the NuRD complex in that is lacks the RBBP4/7 subunits. The CoREST protein 
directly interacts with HDACs 1 and 2 through its N terminal domain, which is required for 
transcriptional repression [299]. The CoREST protein also appears to be the scaffold protein for 
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complex assembly as it also interacts with the REST and LSD1 subunits [300]. The interaction of 
CoREST with LSD1 also stimulates its H3K4 demethylase activity [301]. Together, LSD1 and 
the HDACs make up the catalytic component of the complex. The other proteins associated with 
the complex are involved in targeting and activation of the complex. 
The BHC80 subunit binds to unmethylated H3K4 through its PHD domain, specifically 
interacting with the first 21 residues of histone 3, but not any other the other histone proteins. 
BHC80 directly interacts with LSD1 [302], and is required for the targeting of LSD1 to 
unmethylated histones, as H3K4 methylation greatly decreases the affinity of BHC80 to histone 
3 [303]. Less is currently known about the function of CtBP subunit and its requirement for 
activity of the complex. CtBP is a binding partner of multiple transcription factors and has been 
shown to direct the repression of target genes through the recruitment of HDACs, possibly 
implicating it in the targeting of the complex, reviewed in [304].  
1.7.3. Histone Methyltransferases 
Set 1 Methyltransferase 
Set1 is the H3K4 methyltransferase that is responsible for methylating histones on the HSV 
genome during lytic infection [128]. A schematic of the core Set1/MLL1 complex is shown 
below in Figure 14. Both the catalytic Set 1 and MLL1 components can interact with HCF-1, an 
interaction partner of VP16, which recruits them to immediate early promoters where they 
function to promote immediate early gene expression.  
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Figure 14: Set1 Methyltransferase Complex 
Protein components of the Set1/MLL1 histone H3K4 methyl transferase, adapted from [305] 
The non-enzymatic core components include AshL2, WDR5 and RbBP5, which form a 
structural scaffold independent of the catalytic components and but can interact with and recruit 
different catalytic subunits. Both RbBP5 and WDR5 are essential for the formation of stable 
complexes with MLL proteins. Additionally, RbBP5 plays a critical role in the organization of 
the complex as it interacts with both Ash2L and WDR5, whereas Ash2L is not necessary for the 
formation of the complex. All three core components are necessary for maximal enzymatic 
action of the histone methyltransferase complex [306]. WDR5 has been shown by crystal 
structure to interact with H3 and is likely involved in the targeting of the complex to 
nucleosomes [307]. Point mutations of this protein have shown it to have two functions: 
maintaining structural integrity of the complex through interactions with RbBP5 and MLL and 
directly contacting H3 for complex recruitment [306]. 
Suv39h1
Suv39h1/2 is one of the main H3K9 methyltransferases and is responsible for the formation of 
pericentromeric and telomeric heterochromatin. The human isoforms of this protein were first 
discovered in 2000 and were shown to have two separate domains, the chromodomain and SET 
domain. In general, chromodomains mediate the targeting of chromatin modifiers to euchromatin 
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or heterochromatin [308]. The SET domain of Suv39h1 is the catalytic domain, is essential for 
H3K9 trimethylation, and is specific only to lysine 9 of H3. Additionally, existing histone 
modifications, especially H3K9 acetylation and H3S10 phosphorylation, can block H3K9 
methylation [309].  
 Immunoprecipitation studies of Suv39h1 have shown that it is part of a larger complex 
containing the additional H3K9 methyltransferases G9a, GLP, and SETDB1, as well as two 
isoforms of HP1, HP1β and HP1γ. The formation of this complex could allow for sequential 
methylation for the establishment of constitutive heterochromatin where SETDB1 or G9a/GLP 
dimethylate H3K9, creating a substrate for further methylation by suv39h1 [310]. Additionally, 
the binding of Suv39h to HP1 increases its affinity for trimethylated H3K9, which would 
increase the affinity of the complex for heterochromatin to enhance targeting [311].  
 
Polycomb complex 1 and 2 
The polycomb repressive complexes are responsible for creating and maintaining facultative 
heterochromatin through the trimethylation of H3K27 and compaction of chromatin. PRC2 
deposits the methyl groups on the histone, while PRC1 binds to trimethylated H3K27 and 
ubiquitinates histone 2A to promote chromatin compaction. The core components of these 
complexes are shown in Figure 15. PRC2 is discussed in detail first since its enzymatic function 
on histones precedes PRC1 recruitment. 
PRC2 is composed of 4 core subunits that are conserved from Drosophila to mammals, 
including EZH1/2, SUZ12, EED and RbAp46/48 (also known as RBBP7/4). The catalytic 
subunit of this complex is the EZH protein, which has two isoforms that differ in their expression 
and function: EZH2 but not EZH1 is expressed in actively dividing cells. EZH2 is the active 
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methyltransferase of PRC2 responsible for methylating H3K27. Unlike other methylases, EZH2 
can successively add three methyl groups. Polycomb complexes containing EZH1 lack this 
ability and instead use a deferent mechanism to repress and compact chromatin [312]. The non-
catalytic subunits EED and SUZ12 are required for complex activity. EED is a WD repeat 
protein that recognizes repressive trimethylated lysines and aids in the targeting of PRC2 to 
trimethylated H3K27 [313]. EED also contributes to the catalytic activity of EZH2 [314]. SUZ12 
contains a C-terminal VEFS domain which promotes assembly of PRC2 and is required for the 
proper methylating function of PRC2 [315]. RbAp46/48 is not required for catalytic activity of 
the complex, but plays a role in complex assembly through interactions with SUZ12 and histone 
binding [316].  
 In addition to these four core components, PRC2 also interacts with other proteins for 
proper functioning. Jarid2 is a member of the Jumonji C family of proteins, but is catalytically 
inactive [317]. It promotes the targeting of PRC2, but functionally represses its activity, possibly 
to allow finer tuning of histone methylation. However, Jarid2 is required for PRC2 function since 
knockdown of the protein greatly reduces overall H3K27 methylation [318]. PCL has been 
suggested to stimulate the methylase activity of the complex and has been shown to recruit the 
complex to target genes through its PHD finger domain [319, 320]. AEBP2 has also been 
identified as a binding partner of PRC2; however, its function has not yet been determined.  
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Figure 15: Polycomb Complexes 
Core components of the mammalian polycomb complexes 1 and 2, adapted from [321] 
Canonical PRC1 is composed of one isoform of each of the four main proteins: Ring1, 
PCGF, CBX, and HPH. The number of isoforms varies between species, but mammalian 
complexes can consist of one of 5 CBX, 2 Ring1, 6 PCGF, and 3 HPH different isoforms [322]. 
Depending on the composition, the function and targeting of the complex is different. Only 
polycomb complexes containing CBX2 and PCGF2 (Mel18) and/or PCGF4 (Bmi1) as well as 
Ring1a and Ring1b were found to bind to trimethylated H3K27, consistent with other data 
showing that CBX2 was the only CBX protein to show affinity for trimethylated H3K27 [323, 
324]. Ring1 is the catalytic component of PRC1 that ubiquinates H2AK119, and its activity is 
enhanced by PCGF4 [325]. Ubiquitination of H2AK119 has been shown to be essential for 
chromatin compaction and repression of gene expression [326].  
1.7.4. Histone Demethylases 
The demethylases responsible for removing repressive methylation of H3K9 and H3K27 are 
localized within the same complex. Figure 16 shows the protein components of this complex.  
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The components of this complex include Set1A/MLL1-5, HCF-1, LSD1, JMJD2, and 
UTX/JMJD3. JMJD2 and LSD1 cooperatively function to demethylate trimethylated H3K9, 
while UTX/JMJD3 demethylates trimethylated H3K79 [124, 327]. The Set1A/MLL1-5 
components are H3K4 methylases and are discussed in the above section. The H3K4 methylation 
mark is an activating mark, so formation of this complex may enable a coupling of repressive 
marker removal to the deposition of activating chromatin modifications. 
Figure 16: Demethylase Complex 
Constituents of the LSD1 demethylase complex, adapted from [122] 
LSD1 and JMJD2 
LSD1 can demethylate both H3K9 and H3K4 to either activate or repress transcription, 
depending on its interaction partners, functioning as a H3K4 demethylase in the REST-CoREST 
complex, and a H3K9 demethylase when in the Set1A/MLL1 complex. Its function in the REST-
CoREST complex was discussed in an earlier section, so this section will focus on its role as a 
H3K9 demethylase.  
While LSD1 is a H3K9 demethylase, it can only demethylate mono or dimethylated 
H3K9, not trimetylated H3K9 [328], indicating that it cannot function alone in H3K9 
demethylation. Rather, it functionally interacts with JMJD2, a second demethylase specific for 
H3K9me3. The JMJD2 protein can only remove one methyl group, leaving a dimethylated H3K9 
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product [327], a substrate for LSD1. Thus, trimethylated H3K9 is processively demethylated by 
the action of first JMJD2 then LSD1.  
UTX/JMJD3 
UTX and JMJD3 are specific to H3K27 methylation marks and can remove the first two methyl 
groups from trimethylated H3K27, but cannot efficiently remove the final methyl group. 
Furthermore, the function of these proteins, when purified, is much less efficient on nucleosomal 
substrates, indicating that there may be additional cofactors or modifications that are necessary to 
stimulate their activity [329]. These two proteins are likely involved in the activation of gene 
expression as monomethylation of H3K27, the product of their enzymatic function, is commonly 
associated with actively expressed genes [330]. UTX and JMJD3 can associate with MLL 
proteins to become incorporated into the H3K4 methylase complex [331]. 
1.8 RATIONALE 
Herpes Simplex Virus infects multiple cell types during the stages of its lifecycle. Productive 
infection begins when the virus contacts the oral mucosa and enters epithelial cells. The virus 
replicates to high titers and gains access to nervous tissue through sensory neurons innervating 
the primary site of infection. The virus then travels up the length of the axon and enters the cell 
body where it replicates to low levels and establishes a lifelong latent infection in the ganglia. 
The virus periodically reactivates to reestablish productive infection, enabling the virus to 
spread. For this reason, HSV affects a large subset of the general population, and poses an 
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especial risk to immunocompromised patients who are more likely to develop resistance to 
acyclovir, the standard treatment. Second line drugs must be administered intravenously and 
have more severe side effects. Currently, there is no treatment to target the latent reservoir or 
permanently block viral reactivation. The potential to develop novel therapies underscores the 
need for a better understanding of the mechanism of reactivation and cellular factors that may 
affect viral transcription. 
During the HSV lifecycle, the virus must transcribe and replicate its genome in two cell 
types – epithelial cells and neurons. These two cell types are vastly different, as epithelial cells 
are constantly dividing, whereas neurons are terminally differentiated and have exited the cell 
cycle. HSV transcription is mediated by host RNA polymerase II and various cellular 
transcription factors and activators. As neurons and epithelial cells have differences in their 
metabolic activity and transcriptional needs, they likely have different abundances of 
transcription factors that would likely affect HSV gene expression.  
Furthermore, it has been shown that neurons and epithelial cells express different histone 
variants, and that the incorporation of these different variants augments chromatin structure in 
different ways. Chromatin plays an important role in the HSV lifecycle and is modified by 
various cellular complexes. During lytic infection in epithelial cells, the genome is in a 
euchromatic state so that viral transcription proceeds robustly. However, during latency, the viral 
genome is repressed in densely packed heterochromatin which greatly restricts transcription. For 
reactivation to occur, the genome must transition back to a euchromatic state, but during the 
early events of reactivation, viral activators must likely function on genomes that are at least 
partially heterochromatic.  
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Therefore, the goals of this study were to determine if HSV transcription varied between 
cell types and if HSV transactivators could function on heterochromatinized templates. More 
specifically, the two goals of this project were to: 
 
1. Characterize the transcriptome of wild type and different HSV mutants in neurons 
and MRC5 cells. 
2. Determine if the main transcription factor ICP4 could access and activate 
transcription from quiescent genomes in neurons and MRC5 cells. 
 
These two goals will be discussed in the following chapters. 
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2.0 TRANSCRIPTION OF THE HERPES SIMPLEX VIRUS, TYPE 1 GENOME 
DURING PRODUCTIVE AND QUIESCENT INFECTION OF NEURONAL AND NON-
NEURONAL CELLS. 
 
 
 
 
2.1 SUMMARY 
 
Herpes simplex virus, type 1 (HSV-1) can undergo a productive infection in non-neuronal and 
neuronal cells such that the genes of the virus are transcribed in an ordered cascade. HSV-1 can 
also establish a more quiescent or latent infection in peripheral neurons, where gene expression 
is substantially reduced relative to productive infection. HSV mutants defective in multiple 
immediate early (IE) gene functions are highly defective for later gene expression and model 
some aspects of latency in vivo. We compared the expression of wild-type (wt) virus and IE gene 
mutants in non-neuronal cells (MRC5) and adult murine trigeminal ganglion (TG) neurons using 
the Illumina platform for RNA sequencing (RNAseq). RNAseq analysis of wild type virus 
revealed that expression of the genome mostly followed the previously established kinetics, 
validating the method, while highlighting variations in gene expression within individual kinetic 
classes. The accumulation of immediate early transcripts differed between MRC5 cells and 
neurons, with a greater abundance in neurons. Analysis of a mutant defective in all five IE genes 
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(d109) showed dysregulated genome wide low-level transcription that was more highly 
attenuated in MRC5 cells than in TG neurons. Furthermore, a subset of genes in d109 was more 
abundantly expressed over time in neurons. While the majority of the viral genome became 
relatively quiescent, the latency-associated transcript was specifically upregulated. 
Unexpectedly, other genes within repeat regions of the genome, as well as the unique genes just 
adjacent the repeat regions also remained relatively active in neurons. The relative 
permissiveness of TG neurons to viral gene expression near the joint region is likely significant 
during the establishment and reactivation of latency. 
 
 
2.2 IMPORTANCE 
 
During productive infection the genes of HSV-1 are transcribed in an ordered cascade. HSV can 
also establish a more quiescent or latent infection in peripheral neurons. HSV mutants defective 
in multiple immediate early (IE) genes establish a quiescent infection that models aspects of 
latency in vivo. We simultaneously quantified the expression of all the HSV genes in non-
neuronal and neuronal cells by RNAseq analysis. The results for productive infection shed 
further light on the nature of genes and promoters of different kinetic classes. In quiescent 
infection, there was greater transcription across the genome in neurons relative to non-neuronal 
cells. In particular, the transcription of the latency-associated transcript (LAT), IE genes, and 
genes in the unique regions adjacent to the repeats, persisted in neurons. The relative activity of 
this region of the genome in the absence of viral activators suggests a more dynamic state for 
quiescent genomes persisting in neurons.  
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2.3 INTRODUCTION 
 
Herpes Simplex Virus 1 (HSV-1) productively replicates in non-neuronal cells at peripheral sites 
of individuals where it gains access to nerve endings of the peripheral nervous system. In sensory 
neurons, the virus can either replicate or it can establish life-long latency, where the viral 
genome is relatively quiescent compared to productive infection. Therefore, the viral genome can 
be expressed to produce progeny virions in both non-neuronal and neuronal cells, but can also 
establish a reversible silent state in some neuron populations. As some studies suggest [332, 
333], there may be differences in how the genome is expressed in neuronal and non-neuronal 
cells, however some aspects of the former study may be explained by viral spread in vivo [334].  
The transcription of HSV genes in non-neuronal cells by RNA pol II [13] is sequentially 
and coordinately regulated [68, 335], generally being described as a cascade where three classes 
of genes are expressed, the Immediate Early (IE), Early (E), and Late (L) genes. IE gene 
transcription is activated in the absence of prior viral protein synthesis by VP16 present in the 
infecting virion [336-338]. The products of IE genes are required for the transcription of the E 
genes, which encode the DNA synthetic machinery. IE and E proteins along with viral DNA 
replication are required for efficient late (L) transcription, the protein products of which mostly 
comprise the virion structure or are required for its assembly. 
Promoters for the genes of the 3 kinetic classes are generally thought to share common 
features. IE gene promoters contain a TATA box [339, 340], elements that are responsive to 
VP16 in the incoming virion, and upstream binding sites for cellular transcription factors [336, 
337, 341]. Early gene promoters that have been characterized contain a TATA box, and upstream 
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binding sites for cellular transcription factors, such as found in the thymidine kinase promoter 
[342, 343]. Late genes that are tightly dependent on viral DNA synthesis contain a TATA box 
and an initiator element [344] at the start sites of transcription [345]. Despite these similarities, 
genes of a particular class may be expressed quite differently.  
While viral cis- and trans-acting elements are a determinant of how individual viral genes 
are expressed, the transcriptional environment in different cell types likely influences the 
expression of the genome as well. When HSV enters sensory neurons, gene expression may be 
repressed and the virus can establish a latent infection. The genome of the latent virus persists in 
a state repressed by heterochromatin [189, 346], where the predominant gene that is expressed is 
the latency associated transcript or LAT [347]. The genome can periodically reactivate to 
produce new virus by a poorly understood process that may involve the initial low-level 
dysregulated expression of the genome [217, 218].  
We and others have utilized a system that employs viral mutants, which are defective for 
the expression of IE genes to model some aspects of latency in vitro [190, 348]. d109 is a mutant 
that does not express the IE proteins, is nontoxic to most cells in culture and its genome is 
relatively quiescent in infected Vero cells or diploid human fibroblasts [190]. d109 genomes 
persist in an endless form in cultured cells [349], as do latent virus genomes in vivo [350]. 
Moreover, the expression of select viral genes from d109 genomes persisting in human 
fibroblasts is several orders of magnitude less than wild-type virus and the genomes are bound 
by heterochromatin [191, 222] as they are in latency. While it is reasonable to pursue this model 
of latency given the similarities with latency in vivo, the expression of mutants such as d109 in 
cells where latency is naturally established has not been studied in detail.  
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The intent of this study was to simultaneously quantify the expression of all the viral 
genes during productive infection with wt virus and during quiescent infection of non-neuronal 
(diploid fibroblasts) and neuronal (adult trigeminal neurons) cells to provide insight into: i) what 
determines the kinetics of expression of individual viral genes, ii) neuronal specific differences 
in viral gene expression, and iii) the expression of the viral genome as it persists in TG neurons. 
Previous approaches to simultaneously quantify the expression of the viral genes have used 
hybridization to microarrays of viral sequences representing the viral genes [351]. In the present 
study we used RNA-sequencing (RNAseq) of cDNA derived from infected MRC5 cells and 
neurons. This method proved to be sufficiently sensitive to measure the expression of all the viral 
genes in the absence of viral activators in MRC5 cells and TG neurons. 
 
 
2.4 MATERIALS AND METHODS 
 
Ethics statement: This study was carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All 
animal procedures were performed according to a protocol approved by the Institutional Animal 
Care and Use Committee of the University of Pittsburgh (protocol number: 1201001B, most 
recently approved January 8, 2014). Appropriate sedatives, anesthetics and analgesics were used 
during handling and surgical manipulations to ensure minimal pain, suffering and distress to 
animals. 
 
 73 
Virus and Cells. Experiments were performed using human embryonic lung cells (MRC5) and 
primary mouse trigeminal neurons. MRC5 cells were obtained from and propagated as 
recommended by the American Type Culture Collection. Neurons were isolated from the 
trigeminal ganglia of 6 week old CD1 mice, as described below. The viruses used in this study 
were d109 (ICP4- ICP0- ICP22- ICP27- ICP47-), d106 (ICP4- ICP22- ICP27- ICP47-), n12 
(ICP4-), and the wild type virus KOS. d109, d106, n12, and KOS viruses were propagated on 
FO6F1, E11, E5, and Vero cells respectively [153, 190].  
 
Generation of neuronal cultures. The trigeminal ganglia (TG) were dissected from six week 
old CD1 mice and neurons were isolated following a protocol similar to a previously described 
procedure [352]. Neurons from the TG of 10 mice were used to seed a 24 well plate. Following 
establishment of cultures, the cells were maintained in Neurobasal-A media supplemented with 
2% B27, 1% Penicillin-Streptavidin, .5mM L-glutamine, 50ng/mL nerve growth factor (NGF), 
glial cell-derived neurotrophic factor (GDNF), and neurturin. Media was changed once per week.  
 
RNA Isolation and Reverse Transcription. 2×106 MRC-5 cells in 60-mm plates were infected 
at a MOI of 10 PFU/cell of d109, d106, n12, or KOS. For the infection of neurons, 106 PFUs of 
d109 or KOS were added to each well. The infection was performed at room temperature for 1 
hour with rocking every 10 minutes. Following infection, the inoculum was removed, the cells 
were washed, and fresh pre-warmed media was added. RNA was isolated with the Ambion 
RNaqueous-4PCR kit by following the included protocol. RNA was harvested at the indicated 
time points by removing the medium and adding 500μl lysis/binding buffer to MRC5 cell 
cultures and by adding 100μl lysis/binding buffer per well to neuronal cell culture. For the 
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neuron cultures, 8 wells were pooled per sample. The following steps are the same for both 
neuron and MRC5 samples. Cells were collected and vortexed. An equal volume of 67% ethanol 
was added. The solution was applied to a filter spin column and centrifuged at 12,500 rpm for 1 
min. The bound RNA was washed with wash buffers 1 and 2/3. The column was centrifuged dry 
to remove residual wash buffer from the column. RNA was eluted in two steps with 60μl and 
20μl 75°C elution solution. The RNA was treated with DNase I at 37°C for 30 min to degrade 
remaining DNA. The DNAse was inactivated with the supplied reagent. 
To generate cDNA, two micrograms of total RNA was reverse transcribed in a reaction 
volume of 20μl containing 0.5μlRiboguard RNase inhibitor (40 U/ul), 1μl 10pM OligodT 
Primer, .5μl MMLV High Performance Reverse Transcriptase (200U/μL), 2μl 100 mM 
dithiothreitol (DTT), 4μl nucleotide mix (2.5mM concentration of each dNTP) and 2μl 10x 
reaction buffer. The reaction tube was incubated at 65°C for 2 min to remove RNA secondary 
structure, and the RT reaction was carried out for 1 h at 37°C. Following completion of the RT 
reaction, the reaction tube was incubated at 85°C for 5 min to inactivate the reverse transcriptase.  
 
Quantitative PCR. RNA was diluted to 1μg in 60μl and cDNA was diluted 1:6 in ultrapure 
water. A master mix containing 0.3μl of each primer (stock concentration, 100 μM), 5μl Applied 
Biosystems SYBR green mix with 1.0μM 6-carboxy-X-rhodamine and .4μl of water for a total of 
6μl for each reaction was made. The primers used in this study were: for gC, 
gtgacgtttgcctggttcctgg, and gcacgactcctgggccgtaacg; for ICP27, gggccctttgacgccgagaccaga, and 
atggccttggcggtcgatgcg. The TK primers were the same primers used in previous studies [191]. A 
96 well plate was prepared with 6μl master mix and 4μl of sample or standard. All samples were 
run in triplicate. Purified viral DNA was used to create a standard curve of 1:10 dilutions from 
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4000000 to 40 copies, which covers the threshold cycle value range for the samples tested. qPCR 
was run on a StepOne Plus real-time PCR machine. The conditions for the run were 95°C for 10 
min and 40 cycles of 95°C for 15 s and 60°C for 1 min. At the end of the run, a dissociation 
curve was completed to determine the purity of the amplified products. Results were analyzed 
using the StepOne v2.1 software from Applied Biosystems and compiled in Microsoft Excel. 
 
RNA-Sequencing. RNA was harvested using the Ambion kit as described above and prepared 
for sequencing following the IlluminaTruSeq RNA Sample Preparation v2 Guide and 
accompanying kit (Illumina, San Diego, CA). The libraries were analyzed for length and 
concentration using the Agilent Bioanalyzer. Samples for an experiment were mixed in 
equimolar concentration and sent to the Tufts University Core Facility, Boston, MA, for 
sequencing.  
Following sequencing, the Illumina reads were uploaded onto the Galaxy server for 
analysis (1,2,3). The reads were first groomed using the Fastq groomer function and trimmed 
from the 3’ end to remove low quality score base reads. The reads were then mapped to the 
appropriate reference genome using the TopHat read mapper. For wt HSV, the strain KOS 
sequence was used (Genbank accession number: JQ780693). For alignments, the terminal 
repeats (TRL and TRS) were removed since they are redundant with the internal repeats. For 
d109, the plasmids used to generate the virus were sequenced [190], and the changes were 
incorporated into the KOS sequence. The terminal repeats were also removed for the purpose of 
alignment. Cufflinks was used to quantify the mapped reads, outputting data in FPKM format. 
Since the number of reads and mapped reads varied between samples, the data was renormalized 
to the total number of reads.  
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2.5 RESULTS 
 
RNAseq analysis of productive infection in human fibroblasts and trigeminal neuronal 
cultures. 
 In order to determine the kinetics of expression of all the HSV genes in non-neuronal and 
neuronal cells, monolayers of MRC5 cells and cultures of adult TG neurons were infected with 
HSV-1, strain KOS. Total RNA was collected at different times post infection, and processed 
and subjected to Illumina sequencing as described in the Materials and Methods. Illumina reads 
were processed and aligned to a modified KOS sequence. Figure 17A shows the percentage of 
total reads that map to the viral genome. The percent of viral reads in the cell rapidly increases 
from less than 5% at 1hpi to over 60% by 6 hpi. This accumulation begins to plateau after 8 hpi, 
where approximately 80% of the total mRNA in the cell is virally derived. Similar results were 
obtained in trigeminal neuron cultures, although the percent viral reads were somewhat reduced 
compared to MRC5 cells. The results in MRC5 cells are consistent with previous studies using 
metabolically labeled RNA from infected Hela cells and hybridization techniques [353], where it 
was found that 25-30% of newly synthesized nuclear polyA+ RNA in the nucleus was HSV 
specific at 2-3 hpi, and this increased to 33% between 5-6 hpi. The same study found that most 
of the polysome associated polyA+ RNA was virus specific at both times. While the previous 
methods differ considerably from ours, the similarity with our results helps validate the 
approach.  
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Figure 17: Evaluation of RNAseq reads from infected MRC5 cells.  
Monolayers of MRC5 cells and cultures of adult trigeminal neurons were infected with HSV-1, 
strain KOS at an MOI of 10 PFU/cell. Total RNA was collected from MRC5 cells at 1, 2, 3, 4, 6, 
8, 12, and 16 hours post infection, and from TG neurons at 2, 4, and 8 hours post infection. 
cDNA was prepared and subject to Illumina sequencing as described in the Materials and 
Methods. Illumina reads were processed and aligned to a modified KOS sequence using the 
TopHat mapper in the Galaxy Cloud software package. A. The percent of sequencing reads 
mapping to the HSV genome relative to the total number of reads. B. Comparison of kinetics of 
ICP27 (UL54) accumulation by RNAseq and RT-PCR. C. Comparison of kinetics of tk (UL23) 
accumulation by RNAseq and RT-PCR. D. Comparison of kinetics of gC (UL44) accumulation 
by RNAseq and RT-PCR. The units for RT-PCR were cDNA copies per ug RNA as determined 
by comparison to standards using CsCl-purified viral genomic DNA. The units for RNAseq are 
reads mapped to the viral genome per million total reads (viral+cell) per kilobasepair (MR per 
MTR per Kb). 
 
 To further validate our approach, we compared the amount of signal from representative 
IE, E and L genes as determined by RNAseq and quantitative reverse transcription PCR (RT-
PCR). Figures 17 B, C and D represent the results from ICP27 (IE), tk or UL23 (E), and gC or 
UL44 (L), respectively. The accumulation of these three genes was similar when measured by 
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RNAseq and RT-PCR, demonstrating that RNA-sequencing is sufficiently sensitive and accurate 
to detect changes in transcript abundance over time, with the obvious additional ability to 
quantitatively compare differences in the expression of many genes.  
 
Figure 18: Locations of RNAseq reads across the HSV genome as a function of time post 
infection in MRC5 cells.  
The locations of reads for each of the time points are shown relative to a map of the mRNA for 
each of the HSV genes. The scales of the graphs were set to normalize to the number of total 
reads to enable qualitative comparison of transcript abundance between different time points. 
The reads and the genome are represented without the long and short terminal repeats since their 
sequences are represented within the internal repeats. The exons of RL2 and UL15 are also 
shown by darker shading. 
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The reads that mapped to the viral genome from the RNA-seq of wt-virus (KOS) 
infection were visualized using the Integrated Genomics Viewer [354]. Figure 18 shows the 
reads as a function of time post infection mapped to the KOS genome. Changes in the expression 
of individual genes over time can readily be seen and in many cases appear to reflect the 
established transcriptional cascade of viral genes. At the 1 and 2 hour time points, signals for the 
immediate early genes, ICP27 (UL54), ICP0 (RL2), ICP22 (US1) and ICP47 (US12) are evident. 
The accumulation of ICP4 is not readily seen at this level of sensitivity. The three peaks between 
111-115kb map to the exons of the ICP0 locus, further validating the precision of RNA 
sequencing for HSV mRNA profiling.  
At 4 hours post infection, the abundance of ICP27 and ICP22 mRNA begins to decline. 
ICP0 abundance continues to increase throughout the infection, but constitutes a lower 
proportion of expressed genes. This is consistent with previous observations [355]. Concurrently, 
early genes begin to be expressed. Thymidine kinase (UL23), located between 37 and 39kb, 
peaks between 3-4 hours post infection. Expression of DNA replication machinery genes ICP8 
(UL29) and polymerase (UL30), between 49 and 52kb and 53.5 and 57kb, respectively, also 
peak at a similar time to UL23. Multiple other early genes show similar expression patterns.  
 Replication of viral DNA begins around 4 hours post infection, which enables or 
enhances the expression of late genes. Many late genes, particularly in the region between the 
genes for gC (UL44) and UL49, predominate at this time. The peak for the mRNA encoding the 
tegument protein VP16 (UL48) appears between 94.2 and 95.7kb. It is expressed as early as 2 
hours post infection, but its abundance continues to increase following DNA replication. UL46 
also shows a similar expression pattern. By contrast, UL44, a true late gene, is not expressed 
until 4 hpi, after which its expression increases significantly. UL10, another true late gene 
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located between 14 and 15.4 kb, does not have a distinguishable peak until 4 hours post infection 
and becomes much more abundantly expressed later in infection.  
We next aligned the reads from the infections of trigeminal neurons to the virus genome. 
The aligned reads of cDNA from mRNA derived from TG neurons infected for 2, 4 and 8 hpi are 
shown in Figure 19. In addition to the reduced abundance of total viral transcripts in TG neurons, 
there were some notable differences in the accumulation of some individual transcripts over the 
8h. VP16 (UL48) accumulation is more abundant early in infection of TG neurons relative to 
MRC5 cells. It has been suggested that VP16 possess promoter elements conferring neuron 
specific transcription [356]. Additionally, there was a larger proportion of the immediate early 
transcript region expressed, including ICP4 (RS1), ICP22 (US1), and ICP47 (US12).  
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Figure 19: Locations of RNAseq reads across the HSV genome as a function of time post 
infection in cultured TG neurons.  
As described in the legend for Fig. 18. 
  
The visual representations of the kinetics of mRNA accumulation (Figures 18 and 19) 
provide a picture of the simultaneous transcription of all the HSV genes on the genome, but they 
lack the sensitivity to accurately reflect the transcription of many of the HSV genes. For 
example, an abundant transcript, such as UL44, may give rise 2 x105 reads, and its peak is 
clearly evident, while poorly transcribed genes, such as UL28 or UL36, are barely visually 
evident (Fig. 18). However, there are approximately 2 x 107 total reads in each of the 
multiplexed samples in Fig. 18, providing sufficient sensitivity to quantify the poorly expressed 
genes such as UL28 and UL36. Therefore, the expression of a subset of immediate early, early 
and late genes was quantified in MRC5 cells and neurons using the Cufflinks software package 
on the galaxy server. The accumulation of transcripts from the IE genes in MRC5 cells and 
neurons are shown in Figure 20A and 20B, respectively. The expression kinetics for ICP27 and 
ICP0 was quantitatively similar in both cells types. The kinetics of ICP4 expression was similar 
between the two cell types, however ICP4 was 2-5 fold more abundant in neurons than in MRC5 
cells. There was a considerable difference in the expression profile of ICP22 (US1). In MRC5 
cells, ICP22 peaked at 4hpi, however transcript abundance continues to increase in neurons.  
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Figure 20: The accumulation of HSV transcripts in MRC5 cells and TG neurons. 
Quantification of IE (α) (A and B), E (β) (C and D), L (γ1) (E and F), and L (γ2) (G and H) 
transcripts in MRC5 cells (A, C, E, and G) and neurons (B, D, F, and H). The units for RNAseq 
are reads mapped to the viral genome per million total reads (viral+cell) per kilobasepair (MR 
per MTR per Kb). 
 
Genes specifying the proteins involved in viral DNA synthesis are considered early 
genes, as is the viral thymidine kinase. Figures 20C and 20D show the kinetics of expression of 
these genes in MRC5 cells and neurons, respectively. UL23, UL29, and UL30 followed the 
established expression profile for early genes, with an increase in mRNA abundance early in 
infection followed by a decrease after 3-4 hpi. Expression of UL42 was the highest expressed 
DNA replication gene reaching maximal expression by 6 hpi and subsequently remaining high 
through the duration of the time course. The number of UL42 specific reads indicates that the 
abundance of this mRNA comprised over 1% of the total polyadenylated RNA in the cell. The 
somewhat delayed peak in the accumulation of UL42 mRNA is consistent with earlier studies 
[357]. Unlike immediate early genes, the expression patterns of these early genes in MRC5 cells 
and neurons were similar, although transcript abundance in neurons was less overall. The read 
abundance of UL5, 8, 52 and UL9 was considerably less than the others and their accumulation 
continued to increase following replication of DNA, reaching their maximal levels late after 
infection. Their accumulation appears to be more consistent with late gene expression kinetics.  
 Late genes (γ) require DNA synthesis for maximum expression and continue to 
accumulate throughout infection. Some L genes, the γ1, also have characteristics of E genes and 
are some of the most abundantly expressed genes of the virus. Figure 20E and 20F shows the 
accumulation of 4 γ1 genes, UL19 (major capsid protein), UL27 (gB), UL48 (VP16), and US6 
(gD) in MRC5 cells and trigeminal neurons, respectively. The transcripts for these genes began 
to accumulate at 2 hpi and continued to accumulate to relatively high levels. VP16 and gB in 
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particular began to accumulate very early in neurons each eventually comprising 0.4% (4x103 
MR/MTR/Kb) of the total mRNA in the cell. γ2 genes require DNA synthesis for their 
transcription. The accumulation of transcripts for 9 γ2 genes in MRC5 cells and TG neurons is 
shown in Figures 20 G and H, respectively. Like the transcripts for early genes (Figures 20C and 
20D), the expression patterns of these late genes were similar in neurons and MRC5 cells. 
However, there was a large difference in the level of accumulation of the different transcripts in 
this group of genes. The three most highly expressed late genes were UL44, UL45, and UL35. 
While displaying similar expression kinetics, the accumulation of UL10, 22, 34, 37, 38, and US8 
were considerably less.  
 
Immediate Early Gene Mutants 
Immediate early proteins of HSV are required for the expression of the remainder of the 
HSV genome [335]. Specifically, ICP4 is required for the expression of viral early and late genes 
[358-360]. Mutants deleted in the ICP4 gene are defective for transcription beyond the IE phase 
[56, 153], such that the expression of a prototypic early gene, UL23 (tk) for example, is 
approximately two orders of magnitude less than that seen in wt virus infection [76]. ICP0 
promotes virus growth and reactivation from latency [361-363]. The deletion of ICP0 from HSV 
already deleted for ICP4 results in the further restriction of viral gene expression [190, 191]. 
Abrogating the expression of all IE genes results in a virus that is not toxic to cell, and persists 
for long periods of time [190] in a repressed heterochromatic state [191, 222] resembling that 
seen with wt virus in vivo [188, 346]. To examine the expression across the entire genome of key 
IE gene mutants, MRC5 cells were infected with KOS, n12, d106, and d109 at an MOI of 10 
PFU/cell for 4h and processed for RNAseq. n12 contains a nonsense mutation in the coding 
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region of ICP4, rendering it non-functional [153]. d106 is mutated such that ICP0 is the only 
intact IE gene and d109 is defective for the expression of all the IE genes [190]. The mapped 
reads from each virus relative to the KOS genome are shown in the same scale in Figure 21A to 
illustrate the disparity in gene expression between the 4 different viruses.  
 
Figure 21: Transcript accumulation in IE mutant-infected MRC5 cells.  
MRC5 cells were infected with KOS, n12, d106, and d109 at a moi of 10 PFU/cell for 4 hr, and 
processed for RNA seq as previously stated. A. Locations of mapped reads relative to the KOS 
genome. The Illumina reads were aligned to the modified KOS sequence as before. The 
maximum on the y-axis is 30,000 reads. B. Quantification of the numbers of reads for select 
HSV genes. 
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Transcription of numerous genes can be seen across the entire KOS genome, while 
transcription of the n12 genome appears to be restricted to the UL39, 40 loci, ICP27 (UL54), 
ICP0 (RL2), ICP4 (RS1), ICP22 (US1), and ICP47 (US12). The levels of ICP0, ICP27 and ICP4 
transcripts are considerably higher in n12-infected cells compared to KOS, consistent with the 
previously defined phenotype of n12 [153]. The expression profiles in Fig 21A of d106 and d109 
are also consistent with their published phenotypes [190]. However, this representation does not 
quantitatively describe the expression of the genome in the absence of the IE proteins. 
Considering there were ~20 million reads in each sample and the percent viral reads were 44, 13, 
4.9 and .07, for KOS, n12, d106, and d109, respectively, then there are a considerable number of 
reads to accurately quantify the relatively low abundance transcription across the genome in 
these mutant backgrounds. For example, while no signal is visible for d109 in Figure 21A, there 
are still 1.4 x 104 viral reads in the d109 sample. Fig. 21B shows the number of reads mapped to 
a particular viral gene per million total reads per kilobase pair (MR per MTR per Kb) for 
selected viral genes in the different mutant backgrounds. The genes are for ICP22 (IE), tk (E), 
ICP8 (E), RR1 (E), dUTPase (E), US3 (L), VP5 (L), UL26 (L) and gB (L). Several observations 
can be made from the results; i. IE genes (when present) are highly expressed in the absence of 
ICP4, ii. In the absence of ICP4 (n12), early and late gene transcripts accumulate to 0.1% to 
5.0% the level seen in wt virus infection. An exception is RR1 (UL39), the transcription of 
which is relatively independent of ICP4, iii. Early and late gene expression is further reduced 3 -
5 fold in the d106 background at this time post infection, and iv. In the absence of IE proteins 
early and late transcription is 3 to 4 orders of magnitude less than wt virus at 4 hpi in MRC5 
cells. For example the total number of reads for the tk mRNA is 3 x 105 and 1.5 x 102, for KOS 
and d109, respectively. 
 87 
Expression from the d109 genome in MRC5 cells is further reduced with time due to the 
ongoing formation of heterochromatin [191]. To examine how this repression affects expression 
across the viral genome, and to further compare expression in MRC5 cells to that in trigeminal 
neurons in the absence of IE proteins, MRC5 cells and TG neuronal cultures were infected with 
d109 at a MOI of approximately 10 PFU/cell. mRNA was isolated at 4, 8 and 24 hours and 7 
days post infection, and analyzed by RNAseq as before. The percent of viral reads from the 
MRC5 samples decreased from 0.07% at 4h to just under 0.01% at 7 days, while the percent viral 
reads in trigeminal neurons was 0.5 % at 4h and a little more than 0.1% at 7days, Figure 22. 
Therefore, the number of viral reads was about 10-fold higher in d109-infected neurons than in 
d109-infected MRC5 cells, suggesting a more transcriptionally active genome in trigeminal 
neurons. This is in contrast to what was seen in KOS infected cells, where the proportion of viral 
mRNA in neurons was less than in MRC5 cells. The locations of the reads are shown in Figure 
22 aligned to a modified d109 genome. Unlike Fig. 21A, the scale of the graphs was chosen to 
view the relatively low level expression across the entire genome. As a consequence the signals 
for UL39, 40, the internal repeats and GFP are off the scale. They are represented in Figure 23. 
Regions where there were no reads are represented by gray areas.  
 
Figure 22: Percent viral reads in d109 infected MRC5 cells and TG neurons. 
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The numbers of reads that mapped to the d109 genome were divided by the total number of reads 
and multiplied by 100. 
 
 The accumulation of gene specific reads can readily be seen. Consistent with the higher 
level of transcription overall, there was a general trend toward higher levels of individual 
transcripts in neurons than in MRC5 cells. For example, the levels of glycoprotein B (UL27), 
ICP8 (UL29), UL30, UL41, UL42 were higher in neurons than in MRC5 cells, even at 7 days 
post infection. While transcription across the d109 genome was detected in neurons at 7 days 
post infection, no transcription was detected from many loci in MRC5 cells at this time as 
indicated by the gray shaded regions. This is not due to a lack of persisting d109 genomes, since 
it can be demonstrated that the provision of ICP0 can quantitatively “reactivate” the quiescent 
d109 genomes in MRC5 cells in this system [222].  
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Figure 23: HSV transcripts synthesized in d109-infected MRC5 cells and TG neurons. 
MRC cells and cultures of TG neurons were infected with d109 (MOI = 10 PFU/cell) for 4h, 8h, 
24h and 7d. The RNA synthesized in the cells was analyzed by RNAseq as before, and the reads 
were mapped to a modified d109 genome. The reads were aligned to the d109 genome. The GFP 
gene is shown in red in deleted ICP27 locus. The maximum on the y-axes of the graphs was set 
to 100 reads. The gray shaded areas indicate regions were there were no reads. 
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 One interesting observation is the pattern of expression in neurons of genes just outside 
the long and short repeat regions. In the short unique region of the genome, expression of the 
US3/4, US5/6/7, and US8/9 clusters is evident, and decreases over the course of 24h. However, 
the abundance of the US3/4 and US8/9 increase from 24h to 7days, as that of US5/6/7 decreases, 
as most of the gene do. Likewise UL1/2 and UL4/5 mRNAs decrease over the course of 24 h, but 
increase at 7 days. This pattern is also in contrast to that of all the other HSV genes in UL.  
In neurons, the pattern of expression of the genes adjacent to the long and short repeat 
regions is also seen within the repeats. Figure 24A shows the region of the d109 genome from 
the LAT promoter proximal region through to US2. Figure 24A also shows the RNAseq reads in 
this region from d109 in neurons. These signals were off the scale in Figure 23. Note the only 
place in this region where there were no reads was in the US1 intron. The expression of this 
region overall was considerably greater than that of genes in the unique long and short regions 
(with the exception of UL39 and GFP). While the numbers of reads in this region generally 
decreased over 24h, they were sustained or increased from 24 h to 7 days. The signal just 
immediately downstream from the previously defined LAT mRNA start site that contains an 
ICP4 binding site [364, 365] increased considerably from 1 to 7 days post infection. The LAT 
start site is indicated by the arrow to the left in Figure 24A and by the 2 small arrows (previously 
defined by primer extension analysis [366]) in Figure 24B. Figure 24B also shows the ICP4 
binding site and the TATA box for the LAT transcript along with the RNAseq reads for d109 in 
neurons at 1 and 7 days post infection. The elevated RNAseq signal begins precisely at the 
previously described LAT mRNA start site, strongly indicating that it is transcribed from the 
LAT promoter.  
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Figure 24: Transcription of the internal repeat region from persisting genomes.  
A. The RNAseq reads from d109-infected TG neurons mapping to the region encoding the LAT 
promoter to US2 are shown relative to features in this region of the genome. The Xba1 site at 
111,151 marks the locus of the ICP0 deletion and the site 113,549 marks the locus of the deletion 
that removed the VP16 responsive elements from the region.The numbers shown are in bp from 
the 5’ end of the modified d109 genome in the parental orientation. The maximum of the Y-axes 
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for the 4 and 8h graphs was set at 7,200 reads, while those for the 24h and 7 day graphs were set 
at 1,800 reads. B. The RNAseq reads for the 1 and 7 day d109-infected TG neuron samples are 
shown in the region of the LAT TATA box, mRNA start sites, and ICP4 binding site. The 
maximum on the Y-axis is 100 reads. The beginning of the signal corresponds to arrow to the left 
in the 7 d graph of panel A. C. The quantification of the reads from the samples in figure 5 for 
select viral genes are shown. 
 
The abundance of transcripts from this region of d109 in MRC5 cells and neurons were 
quantified and plotted in Figure 23C. The XbaI site at 111,151, Figure 24A marks the locus of 
the ICP0 deletion in d109 [190], therefore the sequence from the LAT mRNA start site to the 
XbaI site (111,151) is collinear with the 5’end of the LAT primary transcript [367]. The region 
quantified and designated LAT in Figure 23C corresponds to the region from the LAT mRNA 
start site to 1 kB downstream. The transcription of this region is quite complicated with the RL1 
gene and the L/STs (orf P) transcripts antiparallel to each other. The L/STs TATA box, mRNA 
start site and ICP4 binding sites are indicated (Figure 24A) [368, 369]. For the sake of clarity and 
because there is a distinct increase in reads on the L/STs start site (right arrow), the 
quantification in Figure 24C represented as L/STs are the reads from the L/STs start site to 1 kb 
downstream. Also quantified in Figure 24C are ∆RS1, the second exons of US1 and US12, GFP, 
UL39, and UL27. Figure 234 shows several results; i. The abundance of all the transcripts in this 
region is higher in TG neurons than in MRC5 cells. ii. The abundance of all the HSV transcripts 
in MRC5 cells decrease with time such that the maximum abundance is less than 1 in 106 at 
seven days (US1) and LAT is undetectable (<1 in 2 x 107). iii. In neurons, the abundance of 
UL27, UL39 and GFP decrease from 1 to 7 days by ~10-fold, whereas the abundance of ∆RS1, 
US1 and US12, and LAT all increase from 1 to 7 days post infection, with LAT increasing the 
most. iv. The numbers of reads for LAT, L/STs, RS1, US1, and US12 reflect a transcript 
abundance for each that is between 1 in 3x103 and 1 in 104of all transcripts in the cell. This 
suggest that this region of the genome is considerable more transcriptionally active in TG 
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neurons than in MRC5 cells, despite repression of the remainder of the viral genome, even in the 
absence of viral activators. 
 
 
2.6 DISCUSSION 
 
Next generation sequencing has emerged as a high throughput methodology to quantify changes 
in transcriptome wide gene expression. RNA-sequencing has been shown to be more sensitive 
for detection of low abundance transcripts and to have a wider range of detection than traditional 
microarrays [370]. The goal of this study was to determine how the presence and absence of 
immediate early proteins impacted viral gene expression in neuronal (TG neurons) and non-
neuronal cells (MRC5). In particular, we were interested in the expression from a virus that 
establishes a persistent quiescent infection in trigeminal neurons as a model for what might be 
occurring during latency. From the RNAseq experiments performed, we have made the 
following findings; i) during productive infection, there are deviations from the established 
cascade paradigm for early genes, ii) the level of expression of late genes largely a function of 
the TATA box and INR, iii) in the absence of immediate early proteins, transcription from the 
viral genome occurs at low level independent of kinetic class, iv) neurons are less restrictive to 
viral transcription than MRC5 cells, and v) genes near the joint/repeat region of the genome, and 
the LAT locus in particular, are more transcriptionally active during persistence in neurons. 
 
Productive Infection Gene Regulation and Promoter Architecture 
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The promoters of HSV early genes are characterized by the presence of upstream 
elements for cellular transcription factors. Several early genes were quantified in Figure 20C and 
D. ICP8 and TK were abundantly expressed. The promoter for tk gene contains three distinct 
upstream elements, two Sp1 binding sites and one CCAAT element [342]. ICP8 also contains 
two Sp1 binding sites. The DNA polymerase promoter contains a degenerate TATA box, and 
one Sp1 binding site [371]. Expression of this transcript is reduced approximately 4 fold relative 
to tk and 2 fold relative to ICP8. UL42 was the most abundantly expressed gene, comprising 
approximately 1% of the total cellular RNA and peaking at 6 hours post infection, consistent 
with previous results [357]. The abundance of these 4 transcripts decreased late after infection. 
The mRNA for the components of the helicase-primase complex UL5, UL8, and UL52 
[372] and the origin binding protein UL9 [373] were expressed with similar kinetics and 
intensity during early time points prior to DNA replication. Expression of these four transcripts 
slowly accumulated throughout the time course to low levels. The UL8 and UL9 mRNA start 
sites have been mapped [374]. UL8 and UL9 both have degenerate TATA boxes and UL8 has a 
Sp1 site 22 bp upstream of the TATA box. UL 9 has been reported to have an upstream Sp1 site, 
however none are evident in the KOS sequence [374]. The UL5 and UL52 mRNA start sites 
have not been determined making it difficult to localize transcription signals, however the only 
potential TATA boxes within 400 bp of these genes consist of 4 A and T bp. 
Therefore, genes with promoters possessing good TATA boxes, TATA boxes that 
matched the consensus sequence, and multiple sites for upstream factors are abundantly 
expressed early after infection and their decline later in infection is pronounced. This represents 
the early gene paradigm. However, it is difficult to fit some genes whose products are clearly 
required for DNA synthesis into this paradigm. Those with poor TATA boxes, lacking upstream 
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elements, are expressed at a low-level, their decline later in infection is not as pronounced, and in 
some cases accumulation continues at a low level (UL52, UL9). This is reminiscent of some 
previous studies with mutant and chimeric promoters [366, 375, 376].  
Late genes (γ2) require viral DNA synthesis for their expression and their promoters 
consist of at TATA box and a initiator element [377]. The promoter elements of the late genes 
represented in Figures 20G and H are shown in Table 1. The expression of these genes varies 
considerably. There are 4 transcripts with abundance above 10,000 mapped fragments per 
million reads, representing the most highly expressed late genes. The three most highly 
expressed genes, UL35, UL45 and UL44, have a TATA box that completely matches the 
consensus sequence and an initiator element with a perfect match to the first 4 bases of the 
consensus. UL10 is expressed to a lesser extent, and has a mismatch in the TATA box. Genes 
expressed to levels below 10,000 have multiple mismatches the TATA box, the first 4 
nucleotides of the initiator element, or a combination of both. There was no apparent correlation 
to the downstream activation sequence, though it likely plays an important role on a gene by 
gene basis. Therefore, the expression of late genes varies considerably, and their levels of 
transcription correlate with the degree of match to both the TATA box and INR element 
consensus, suggesting that the ability of TFIID to bind to the promoter is the main determinant in 
late gene transcription. 
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 TATA Box INR DAS 
*Consensus TATAAA YYANWYY GAGNNYGAG 
UL10 TAAAA GCACAC None 
UL22 AATAAAA TCATAAA GAGTGCCAG 
UL34 TATAAA GCAGAC CACGGCGAG 
UL35 TATAAA CTAATCG None 
UL37 TATAACA TCGCAAC GAGGGCCGC 
UL38 TTTAAA CCAGTCG GAGGCGGTAG 
UL44 TATAAA CTACCGA GAGGCCGCA 
UL45 TATAAA TCATCCT GGCGTGGAG 
US8 ATTTAA CTTCTGG GAGCCCAAC 
 
Table 1: Promoter elements of γ genes.  
The bold letters designate mismatches between the specific gene element and the consensus 
sequence.  
 
γ1 genes are transcribed early after infection and their synthesis increases after DNA 
replication. Four γ1 genes are presented in Figures 20 E and F. This group of genes is more 
uniform in its expression relative to the other groups of genes and is represented by a minimum 
of 1% of the total reads (virus + cell). The early and sustained high level of expression is most 
likely due to the presence of a TATA box INR and binding sites for upstream factors in their 
promoters [378]. The binding sites for upstream factors enables expression early after infection, 
and the INR allows for the continued expression late after infection. 
We hypothesize that late after infection, cellular activator function and the activity of 
ICP4 on early promoters becomes less active. We have shown that Sp1 gets phosphorylated after 
DNA replication and is less active in vitro [81], and that TFIIA, which is required for the 
activation of tk by ICP4 in vitro, decreases late after infection [82, 84]. In addition, upstream 
activators require a form of the mediator complex for activation, and we have shown that as 
infection proceeds, ICP4 interacts with a form of the mediator complex that is often associated 
with repression of transcription [79]. Therefore, weaker promoters, such as UL8 or UL9, which 
are not activated to the same extent by upstream factors such as Sp1, might not show as dramatic 
 97 
a decrease, or any at all, in activity late after infection. The sustained high-level activity of late 
genes is most likely a function of the ability of ICP4 to activate transcription through the INR 
sequence present at the start site of late genes [81, 88].  
 
Gene Expression during quiescent infection. 
HSV mutants engineered to not express viral activators can establish a quiescent infection 
in cells in culture such that their genomes are transcriptionally repressed and persist in cells [190, 
348, 379]. Heterochromatin forms on d109 genomes persisting in MRC5 cells [191, 222], 
reminiscent of the structure of latent viral genomes [346, 380]. We have also shown that d109 
genomes may not be as tightly repressed in TG neurons as in non-neuronal cells in culture based 
on GFP transgene expression and the ability to reactivate quiescent virus [381]. Therefore, we 
sought to compare the expression of the entire d109 genome in MRC5 cells, as a model for non-
neuronal cells, and TG neurons.  
Trigeminal neurons were significantly more permissive for the expression of genes across 
the persisting d109 genome than MRC5 cells, Figures 23 and 24. The MRC5 cells are 
presumably more homogeneous than these TG cultures, which are known to contain populations 
of neurons that differ in their permissiveness for LAT expression [352]. Therefore it is possible 
that some infected neurons are more permissive for HSV gene expression than others. Moreover, 
expression bore little relation to kinetic class. This “dysregulated” pattern of HSV gene 
expression has been seen in two different systems when reactivation stimuli were applied to 
latent HSV [217, 218]. In our experiments, the persisting genomes are void of genes that are 
thought to activate viral early and late genes, and since the infected neuronal cultures are 
maintained in NGF, known reactivation stimuli were not applied.  
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The elevated level of transcription of persisting vial genomes in neurons relative to non-
neuronal cells most likely is due to the different transcriptional environment in neurons. In 
mammalian cells, there are three different histone H3 variants, H3.1 H3.2 and H3.3. During 
differentiation of neurons, the abundance of variants H3.1 and H3.2 decrease while H3.3 
accumulates [382]. H3.1 contains a combination of both activating and repressive modifications, 
H3.2 is enriched in inactive marks, and H3.3 is enriched in activating markers and is localized to 
transcriptionally active regions [383-385]. The association of H3.3 with the viral genome has 
been shown to facilitate lytic gene expression [117]. Perhaps H3.3 facilitates transcription from 
d109 genomes in TG neurons, while H3.1 and 3.2 restrict gene expression in MRC5 cells. This 
remains to be studied. 
 While the d109 genome in general is more transcriptionally active in TG neurons than in 
MRC5 cells, a large majority of the transcripts in neurons at 7 days post infection map to loci 
around the joint regions and in the unique short region of the virus, Figures 23 and 24. There are 
several possible explanations for this. i) Neuronal specific promoters could be directing the 
expression of all these genes. With the exception of LAT, which is generally thought to possess a 
neuronal specific promoter, it is unlikely that all of these genes (UL1, 2, 4, 5, US1, 3, 4, 8, 9, 12 
RS1, and LAT) have neuron specific promoters. The underlying basis for their enhanced 
expression more likely has to do with a general structural property of the region. ii) Perhaps the 
high G+C content of the internal repeats relative to rest of the genome results in reduced 
occupancy of repressive chromatin in TG neurons. iii) It is also possible that chromatin 
insulators, DNA elements that function to separate euchromatic and heterochromatic areas of the 
genome [386, 387] are involved. Seven distinct regions containing CTCF binding sites have been 
identified in the herpes genome [388]. These are all located in the repeat region of the genome 
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and 5 remain in d109. Two specific CTCF binding sites surrounding the LAT enhancer have 
been shown to function as enhancer-blocking elements and maintain the localization of 
euchromatin to the LAT locus [204]. The presence of these elements could explain the specific 
upregulation of LAT expression during persistence of d109 in neurons. Other insulator elements 
are located surrounding other immediate early genes near in the repeat regions [203]. The 
presence of these insulators could slow the accumulation of heterochromatin in the regions, 
enabling low-level transcription of IE genes in the absence of VP16.  
 The physiological consequences of the elevated low-level expression of genes in the joint 
region are not known. However, an intriguing possibility involves the interplay between HSV 
gene products and microRNAs encoded in this region [210, 389]. During latent infection, the 
primary latency associated transcript serves as a precursor to several miRNAs [210], which may 
target ICP4 and ICP0 [208]. The low-level expression of the IE genes and miRNAs in this region 
could provide the basis for the ability of the virus to reactivate in a regulated way, independent of 
viral activators.  
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3.0 FUNCTION OF HERPES SIMPLEX VIRUS TYPE 1 ICP4 ON QUIESCENT 
GENOMES 
3.1 SUMMARY 
During the process of reactivation from latency, the herpes simplex virus genome undergoes 
epigenetic changes to transition from a heterochromatic to a euchromatic state. Therefore, during 
process of reactivation, it is likely that viral activators function on genomes that are partially 
heterochromatic. ICP4 is promiscuous activator of polII transcription that functions in part by 
binding to the genome. To study the interactions of ICP4 with a heterochromatic genome, we 
used a quiescent model of latency in which a virus that does not express immediate early genes 
persists in cells and acquires epigenetic markers similar to in vivo latency, along with adenovirus 
vectors to deliver the activators ICP4 and ICP0 to quiescently infected MRC5 cells and TG 
neurons. Changes in transcription, chromatin and ICP4 binding, were quantified using RNAseq, 
ChIP and ChIPseq. We found that in MRC5 cells, ICP4 alone was not able to bind to the viral 
genome or induce transcription, suggesting that viral chromatin blocked access of ICP4 to the 
genome and prevented it from inducing the expression of viral genes. When ICP0 was present, 
ICP4 binding was significantly enhanced along with a decrease in histone H3 occupancy and an 
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increase in viral transcription. However, in neurons ICP4 was more efficient in inducing 
transcription from the quiescent genome in the absence of ICP0. These results suggest that: i. 
ICP4 cannot access and therefore cannot activate genomes repressed by heterochromatin, such as 
in quiescently infected MRC5 cells. ii. ICP0 can relieve the repression enabling ICP4 to bind to 
the genome and activate transcription. iii. Quiescent genomes in trigeminal neurons exist in a 
state that allows ICP4 to access the genome and activate transcription independent of ICP0.  
3.2 IMPORTANCE 
During the process of reactivation, the viral genome transitions from a heterochromatic to a 
euchromatic state. During this process, viral activators likely function on genomes that are 
partially heterochromatic. An HSV mutant defective in immediate early gene expression 
establishes a quiescent infection and acquires chromatin modifications similar to in vivo latency. 
We quantified gene expression induced from the quiescent state in both neuronal and non-
neuronal cells following adenovirus mediated delivery of ICP4 and ICP0 by RNAseq and 
quantified ICP4 and histone occupancy on the viral genome by ChIP and ChIPseq. We found 
that ICP4 alone was able to bind to and activate transcription from quiescent genomes in neurons 
but not in non-neuronal cells, suggesting that neurons more loosely repress the genomes, 
possibly due a different type of chromatin deposited on the genome. The looser repression in 
neurons may allow for a more delicate regulation of reactivation where small increases in 
ICP0 or ICP4 expression are balanced by miRNA silencing to maintain the latent state.  
3.3 INTRODUCTION 
 102 
 
Herpes simplex virus 1 (HSV-1) establishes a latent infection, which is characterized by a 
relatively low abundance of viral transcription, in the ganglia innervating the primary site of 
productive infection [390]. The mechanism of viral genome silencing and repression has been an 
area of continuing study. Several early key observations identified epigenetics as a major 
regulatory mechanism, citing histone deposition and modification of histone tails as mechanisms 
for affecting the expression of latent genomes [187, 189, 346]. These modifications and their 
biological significance have been studied in relation to the regulation of viral transcription, but 
are still not fully characterized. 
The epigenetic state of the viral genome differs between the productive and latent phases 
of infection. Lytic replication is characterized by relatively nucleosome free promoter regions, 
and genes with loosely spaced nucleosomes rich in histone acetylation [134, 135]. VP16 and 
ICP0 are thought to establish this euchromatic state early in infection through interactions with 
multiple cellular chromatin modifiers [140, 141, 380, 391-393]. However, when these viral 
proteins cannot counteract cell mediated silencing, the virus establishes a latent infection in 
which the histones on the viral DNA become deacetylated and methylated, and the viral genome 
is repressed in heterochromatin [388]. Markers of both facultative [118, 188] and constitutive 
[189] heterochromatin have been reported, as well as components of the polycomb repressive 
complex and HP1, which maintain the heterochromatic architecture [196]. Latency is not 
permanent, as cellular stress and other unknown environmental factors can induce reactivation 
[394, 395].  
During reactivation of the virus, the viral chromatin becomes acetylated, dispersed, and 
lytic transcription resumes [203, 396], yet the mechanism underlying this process is not well 
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understood. Numerous studies have focused on the reactivation phenotype of different mutant 
viruses and have yielded varying results, likely due to the complex interplay between viral 
activators during this process. We and others have shown that ICP0 can derepress the viral 
genome through reversing constitutive heterochromatin marks, dissociating HP1, and increasing 
histone acetylation [222, 223, 397], which may or may not be required for other activators, 
including the main viral transactivator ICP4, to function. ICP4 is the main transcriptional 
activator of HSV-1 as it regulates the transcription of most viral genes [56, 77, 153]. It binds to 
the genome and interacts with and recruits multiple cellular transcriptional complexes including 
Mediator, TFIID, and chromatin remodeling proteins during lytic replication [79, 155]. 
In the early stages of reactivation, it is likely that viral activators, such as ICP0 and ICP4, 
function on genomes with heterochromatic character to both cause derepression of the viral 
chromatin and activate transcription. Previously, we have created and characterized a mutant 
virus, d109, which is repressed in heterochromatin similar to latency in vivo [190, 191]. To study 
these activators, we adopted an adenoviral expression system to deliver these proteins into d109 
quiescently infected MRC5 cells and murine trigeminal neurons, since previous studies in our lab 
have shown a difference in d109 transcription between the two cell types. The aim of this study 
is to investigate the ability of ICP4 to bind to and activate transcription from a heterochromatic 
genome in neuronal and non-neuronal cells.  
 
 
 
3.4 MATERIAL AND METHODS 
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Virus and Cells. Experiments were performed using MRC5 cells (human embryonic lung cells), 
which were obtained from and propagated as recommended by the American Type Culture 
Collection. Neurons were isolated from the trigeminal ganglia of CD1 mice as described below. 
The viruses used in this study were the IE mutant virus, d109, and several adenovirus vectors. 
The d109 virus was propagated on complementing F06F1 cells as previously described [190]. 
Adenovirus vectors expressing ICP0, ICP4, and beta-galactosidase were created using the 
Invitrogen pAd/CMV/V5-DEST system (V493-20), referred to as Ad0, Ad4, and AdZ 
respectively. The adenoviruses were E1 and E3 deficient and were propagated on the 
complementing 293A cell line.  
 
Neuron Isolation. Six week old CD1 mice were euthanized and perfused with saline solution. 
The trigeminal ganglia were dissected and neurons were isolated following a previously 
established protocol [87]. Neurons from 10 mice ganglia were pooled and seeded into 24 well 
plates. Following establishment of cultures, the cells were maintained in Neurobasal-A media 
supplemented with 2% B27, 1% Penicillin-Streptavidin, .5mM L-glutamine, 50ng/mL nerve 
growth factor (NGF), glial cell-derived neurotrophic factor (GDNF), and neurturin. Media was 
changed once per week.  
 
Infections. MRC5 cells were infected with d109 at a multiplicity of infection (MOI) of 
10PFU/cell in TBS (recipe) at room temperature for 1 hour with rocking every 10 minutes. After 
adsorption, the inoculum was removed and DME (Dulbecco's modified Eagle's medium) 
containing 5% fetal bovine serum (FBS) at 37º was added. Infected cells were maintained at 37º 
for 24 hours. After 24 hours, the media was changed and the cells were moved to 34º to slow the 
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division of cells while quiescence was established. The media was changed at 3 and 6 days post 
infection. At day 7, the media was removed and saved and the cells were then superinfected with 
adenovirus expressing ICP0, ICP4, and B-galactosidase, termed Ad0, Ad4, and AdZ respectively 
as diagramed in Figure 25A. All adenovirus infections were done at a MOI of 10 PFU/cell in 
TBS. Following infection, the inoculum was removed and the saved media (kept at 37º) was 
added back to the cells. This point was considered time 0. Cells were harvested at the indicated 
times for transcriptional or epigenetic analyses. Infection of neurons was similar, except that they 
were done in neuron media instead of TBS to maintain NGF in the media. Additionally, the cells 
were washed with warm media following infection, and the first media change occurred at 6 days 
post infection. All infections were done with 107 PFU/mL using 100uL of inoculum.  
 
ChIP. Chromatin immunoprecipitation (ChIP) was carried out as previously described, with 
some modifications [191, 222]. A total of 5e6 MRC5 cells were seeded into 100mm dishes and 
infected as described above. Cells were prepared for ChIP using the following protocol. Media 
was aspirated from cells and replaced with prewarmed crosslinking buffer: 5% media 
supplemented with 1% formaldehyde and .15% sodium bicarbonate. Crosslinking was done for a 
total of 10 minutes at 37°. The cells were washed 2 times with TBS + Protease inhibitors 
(Protease inhibitors (PI) are .4uM aprotinin, 2uM pepstatin, 0.15mM tosyllysinecholormethyl 
ketone hydrochloride (TLCK), and 1mM phenyl methyl sulfonyl fluoride (PMSF). Cells were 
then scraped into TBS+PI and centrifuged for 15 minutes at 4 degrees at 3000rpm. The 
supernatant was aspirated and the cells were resuspended in 500uL sodium dodecyl sulfate 
(SDS) lysis buffer (1% SDS, 50mM Tris-HCl pH8.1, 10mM + PI). The cells were incubated for 
15 minutes on ice, transferred to Eppendorf tubes, and incubated on ice for 15 minutes. The cells 
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were sonicated for 6 10 second pulses at 30% output. The cells were then centrifuged for 15 
minutes at 14000rpm at 4 degrees. The supernatant was diluted 1:11 in dilution buffer (.001% 
SDS, 1.1% Triton X-100, 167mM NaCl, 1.2mM EDTA, 16.7mM Tris-HCl pH 8.1 + PI). The 
samples were precleared by adding 120uL protein A agarose beads (Millipore) and rotating the 
samples for 2 hours, centrifuging 15 minutes 3000rpm, and collecting supernatant. This process 
was repeated for a total of 2 times. The samples were then added to 50uL of protein A agarose 
beads containing either H3 (Abcam ab1791) or N15 antibody. The samples were incubated with 
the beads overnight with rotation at 4º. The beads were washed twice for 5 min each in low-salt 
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mMTris-HCl pH 8.1, 150 mMNaCl), 
twice for 5 min each in high-salt buffer (0.1% SDS, 1% Triton X-100, 2mM EDTA, 20 mMTris-
HCl pH 8.1, 500 mMNaCl), once for 5 min in LiCl buffer (0.25 mM LiCl, 1% NP-40, 1% 
deoxycholate, 1 mM EDTA, 10 mMTris-HClpH 8.1), and three times for 5 min each in Tris-
EDTA (TE) buffer (10 mMTris-HClpH 8.0,1 mM EDTA). The samples were eluted from the 
beads in two steps with 250 μl of elution buffer (1% SDS, 0.1 M sodium bicarbonate) and 
rotation for 20 minutes. Twenty microliters of 5 M NaCl was added to each sample, and the 
cross links were reversed overnight through incubation at 65 degrees. Thirty-one microliters of a 
proteinase K mixture (1:2:1 0.5 M EDTA–Tris-HCl pH 6.5–20 mg/ml proteinase K) was added 
to each tube, and the samples were incubated at 55°C for 2 h. The DNA was purified using 
phenol-chloroform-isoamyl alcohol (25:24:1) extractions. The purified DNA was precipitated 
with the addition of 1mL 100% ethanol, washed with 70% ethanol and resuspended in 60uL 
water. The immunoprecipitated DNA was quantified through qPCR. 
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ChIPseq: immunoprecipitated DNA was processed for the generation of Illumina sequencing 
libraries according to the Illumina TruSeq ChIP preparation protocol. ChIPseq libraries were sent 
to the Tufts University Core Facilty, Boston, MA, for sequencing. The analysis of the sequencing 
data was similar to that described previously [87] except that Bowtie was used instead of 
TopHat. 
 
RNA isolation. MRC-5 cell were seeded into 60mm dishes at a density of 2e6 cells per dish and 
infected with d109 at an MOI of 10 PFU/cell. The adenovirus infections were the same as 
described above. RNA was isolated with the Ambion RNaqueous-4PCR kit by following the 
included protocol. RNA was harvested by adding 500μl lysis/binding buffer to MRC5 cell 
cultures and by adding 100μl lysis/binding buffer per well to neuronal cell culture. For the 
neuron cultures, 6 wells were pooled per sample. The following steps are the same for both 
neuron and MRC5 samples. The cells were scraped into the lysis buffer and collected in a 1.5mL 
Eppendorf tube. An equal volume of 67% ethanol was added. The solution was pipetted into a 
filter spin column and centrifuged at 13000 rpm for 1 min. The column was washed with wash 
buffers 1 and 2/3 and centrifuged dry to remove residual wash buffer. RNA was eluted in two 
steps with 60μl and 20μl 75°C elution solution. The RNA was treated with DNase I at 37°C for 
30 min to degrade remaining DNA. The DNAse was inactivated with the supplied reagent in the 
kit. 
 
Reverse Transcription and qPCR. Two micrograms of RNA were mixed with 1μl 10pM 
OligodT Primer in a total volume of 11μl. The tube was incubated at 65°C for 2 min to remove 
RNA secondary structure. Following the incubation, the tube was cooled and the following 
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reagents were added: .5μlRiboguard RNAse inhibitor, .5μl MMLV High Performance Reverse 
Transcriptase (200U/μL), 2μl 100 mM dithiothreitol (DTT), 4μl nucleotide mix (2.5mM 
concentration of each dNTP) and 2μl 10x reaction buffer. The RT reaction was carried out for 1 
h at 37°C. Following completion of the RT reaction, the reaction tube was incubated at 85°C for 
5 min to inactivate the reverse transcriptase. 
RNA was diluted to 1μg in 60μl and cDNA was diluted 1:6 in ultrapure water. A master 
mix containing 0.3μl of each primer (stock concentration, 100 μM), 5μl Applied Biosystems 
SYBR green mix with 1.0μM 6-carboxy-X-rhodamine and .4μl of water for a total of 6μl for 
each reaction was made. The primers used in this study were: VP16ds, TKds, DNApolds, 
ICP8ds, gCds, and RR1ds. The sequences of the primers used are: 
RR1ds (F: CGATCCAGATTCCAAAGTGCCCR: CGGTTTCCAGCCAGCGGTTA),  
VP16ds (F: CAGGCCCTCGATGGTAGACCCGTAAR: 
GGTGTTGATTCGGGCGAAGTTGGAC),  
ICP8ds (F: CGAACTTGCGGGTGCGGTCAAAR: CATGGTCGTGTTGGGGTTGAGCATC) 
DNA polds (F: GCTTCGATATCGAATGCAAGGCGGR: 
CGAGCGAAAACAGGAGGACGTGCTC) 
TKds and gCds primers were the same primers used in previous studies [191]. A 96 well plate 
was prepared with 6μl master mix and 4μl of sample or standard. All samples were run in 
triplicate. D106 viral DNA was used to create a standard curve of 1:10 dilutions from 4000000 to 
40 copies, which covers the threshold cycle value range for the samples tested. qPCR was run on 
a StepOne Plus real-time PCR machine. The conditions for the run were 95°C for 10 min and 40 
cycles of 95°C for 15 s and 60°C for 1 min. At the end of the run, a dissociation curve was 
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completed to determine the purity of the amplified products. Results were analyzed using the 
StepOne v2.1 software from Applied Biosystems and compiled in Microsoft Excel. 
RNAseq: RNA was isolated using the procedure described above and prepared for deep 
sequencing according to the manufacturer’s instructions (Illumina) and as described previously 
[87]. 
3.5 RESULTS 
Optimization of Infection 
In this study, adenoviruses expressing ICP0, ICP4, and Beta-galactosidase driven by the 
HCMV immediate early promoter were used to infect MRC5 cells and TG neurons that were 
quiescently infected with d109 to determine how ICP4 in particular functions on quiescent 
genomes repressed by chromatin. Time courses of protein expression from the adenoviruses 
were performed to determine the kinetics of protein expression (data not shown). Using this 
scheme, we next showed that the simultaneous presence of ICP4 and ICP0 did not greatly affect 
the abundance of either protein relative to the single infections (Figure 25B). While ICP0 slightly 
enhanced the transcription of ICP4, (Figure 25C) it did not lead to an increase in ICP4 protein 
abundance (Figure 25B). ICP4 did cause a small reduction in the amount of ICP0 protein 
expressed (Figure 25B).  
As a first step to determine the effects of adenovirus-expressed ICP4 and ICP0 on the 
expression of quiescent d109 genomes, MRC5 cells were infected with d109 and the indicated 
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adenoviruses as outlined in Figure 25A. The HCMV immediate early promoter drives the 
expression of GFP in the d109 genome. The cells were visualized by fluorescence microscopy to 
monitor the expression of GFP, Figure 25D. Very few GFP-expressing cells were found in the 
mock, AdZ-, and Ad4- infected cultures. Consistent with previous results [222], infection by 
Ad0 resulted in the induction of GFP expression. The simultaneous presence of ICP4 did not 
significantly affect the abundance of GFP. 
Figure 25: Adenovirus Infection Protocol 
A. The schematic for the infection protocol is shown. MRC5 cells or neurons were infected with
d109 for 7 days to establish quiescence. Cells were then superinfected with Adenoviruses
expressing ICP0, ICP4, or LacZ. Time points were taken at 36 hours for Ad0, AdZ and mock,
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and at 12 hours for Ad4. B. Western blot analysis of protein expression from adenovirus vectors, 
with GAPDH as a loading control. C. Quantification of ICP4 RNA expression from adenovirus 
determined by RNA-seq analysis. D. Phase contrast and fluorescence microscopy images of 
quiescent cells superinfected with adenovirus. GFP is constitutively expressed in the absence of 
epigenetic repression. 
 
Activation of Quiescent Genomes in MRC5 cells by ICP4 
MRC5 cells were infected with d109 for 1 week and then superinfected with adenovirus 
as described above. RNA was extracted and prepared for Illumina sequencing. Individual reads 
were mapped to a modified d109 genome in which duplicated sequences and sequences that were 
also present in the adenovirus vector were removed. The aligned reads are displayed on 
equivalent scales and are shown in Figure 26A. The gray regions represent areas that are devoid 
of reads. GFP and areas in the joint region, located around 108kb and 115kb respectively, were 
robustly transcribed in the Ad0 and Ad0+4 samples and therefore their signals fall outside of the 
range of the scale presented. The scale was chosen so that lower abundance reads could be easily 
visualized.  
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Figure 26: RNAseq of Quiescently Infected MRC5 Cells Superinfected with Adenovirus 
Monolayers of MRC5 cells were infected with d109 at a MOI of 10 PFU/cell. Quiescence was 
established for 1 week and the cells were then superinfected with adenovirus at a MOI of 10 
PFU/cell. Cells were harvested at 12 hours post infection for Ad4, and at 36 hours for Ad0, AdZ, 
mock, and Ad0+4 staggered. cDNA was prepared and subjected to Illumina sequencing as 
described in the Materials and Methods. Illumina reads were processed and aligned to a modified 
d109 sequence using the TopHat mapper in the GalaxyCloud software package. A. Reads from 
the RNAseq are shown mapped to the d109 genome. The reads were normalized to the total 
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number of reads to reduce variation from read density during sequencing. Grey regions represent 
areas of the genome completely devoid of transcription B. Quantification of a few representative 
genes from the RNAseq data set using the cufflinks software package. The Y axis is graphed as 
Mapped Fragments per Kilobase pair per Million Total Reads (MR per MTR per Kb). C.qRT-
PCR quantification of viral transcripts. 
 
The viral genome was essentially silenced during quiescence in MRC5 cells, as 
evidenced by the near lack of viral transcription, Figure 26A mock, consistent with previously 
published data [87]. When AdZ was added, there was no significant change in the expression of 
viral genes, evidenced by a lack of change in the mapped reads profile and an insignificant 
increase in the percent viral reads mapped, demonstrating that the viral vector alone did not 
induce changes in transcription. When Ad4 was added alone, it also did not induce any 
noticeable changes in gene expression. Therefore, there was no difference between the read 
profile of mock, AdZ and Ad4 infected cells, indicating that ICP4 alone could not activate the 
quiescent genome in MRC5 cells. 
However, gene expression increased following the expression of ICP0, consistent with 
previous studies. The percent mapped increased to 8.2%, with ribonucleotide reductase, GFP and 
genes around the joint being the most abundantly expressed, Figure 26A and 26B. When Ad4 
was added to quiescent cells that had been infected with Ad0, viral transcription increased above 
levels seen with ICP0 alone, Figure 26A. Components of the DNA replication machinery were 
highly induced by ICP4 including UL29, UL30 and UL42. Some leaky late genes, most notably 
UL19 (ICP5), UL27 (gB), UL48 (VP16), US6 (gD), US7 (gI) and US8.5/US9 were also induced. 
However, true late gene expression was not significantly induced, as seen in the traces for UL36 
(VP1/2), UL41 (vhs) and UL44 (gC).  
The cufflinks software was used to quantify expression of a few viral genes, TK, VP16, 
ICP8, UL39 (RR1), and DNA polymerase, Figure 26B. The most highly expressed gene in Ad0 
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and Ad0+4 treated cells was ribonucleotide reductase (UL39), however ICP4 did not induce its 
expression above ICP0 alone. Some increases in viral transcription between AdZ and Ad4 
treated cells could be detected, however, since the number of viral reads was so few, these 
changes were not statistically significant. RT-PCR was used to validate the cufflinks data and is 
shown in Figure 26C. Increases in gene expression between mock and Ad0 samples were 
consistent between the two methods. For TK, VP16, ICP8 and polymerase the fold increase in 
mRNA resulting from the addition of ICP4 on top of ICP0 was approximately 10-20 as measured 
by both mapped reads and RT-PCR.  
 The data in Figures 26B and 26C also demonstrate a small increase in the abundance of 
TK, ICP8, VP16 and pol mRNA by the addition of ICP4 alone relative to mock superifected 
cells. However, the absolute level of transcripts is many orders of magnitude less than with ICP0 
and ICP0+ICP4. We believe this represents transcription that is occurring in small subpopulation 
of cells and will be discussed in the next section. 
  
Chromatin restricts the binding of ICP4 to the quiescent genome in MRC5 cells 
The inability of ICP4 to activate quiescent genomes on a global scale is most likely 
related to its ability to access and/or function on the quiescent genomes. To investigate this, 
MRC5 cells were infected with d109 and the adenovirus vectors as done in the gene expression 
experiments above. Cells were harvested and ChIP was performed for ICP4 and H3 abundance at 
the TK and gC promoters, representative early and late gene promoters, respectively. ICP4 
binding to the genome was undetectable above background at both promoters when ICP4 alone 
was present, Figure 27A&B. However, when ICP0 was present, ICP4 association with the viral 
genome significantly increased. H3 occupancy remained high when the Ad4 virus was added, 
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but in the presence of ICP0, H3 occupancy decreased at both promoters, Figure 27C&D, 
consistent with previous results [222]. Therefore, the binding of ICP4 was inversely correlated to 
histone 3 occupancy, suggesting that the presence of chromatin on the viral genome blocked the 
binding of ICP4 and that ICP0 enabled ICP4 to activate quiescent genomes by removing 
repressive chromatin.  
Figure 27: ICP4 binding and Histone Occupancy on Quiescent Genomes in MRC5 Cells 
The four panels are from three independent chromatin immunoprecipitation experiments on 
adenovirus superinfected quiescently infected cells. An ANOVA analysis was run to determine 
significance between the multiple conditions and then a t-test was done to determine significance 
between Ad4 and Ad0+4 treated samples. The data is shown as a percent immunoprecipitated 
relative to the input. The promoters analyzed were thymidine kinase (TK), a representative early 
gene and glycoprotein C (gC), a representative late gene. A. H3 IP on TK promoter B. H3 IP on 
gC promoter C. ICP4 IP on TK promoter D. ICP4 IP on gC promoter. 
The binding of ICP4 was also measured by ChIPseq in which immunoprecipitated 
chromatin was prepared for Illumina sequencing. Reads were mapped to the viral genome and 
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are shown in Figure 28. The grey regions represent areas devoid of reads and hence ICP4 
binding. When ICP4 was expressed alone, it was unable to bind to the genome, as there was no 
difference in peak density between the mock and Ad4 treated samples. However, when ICP0 was 
present, ICP4 binding increased genome wide, confirming the ChIP results.  
 
Figure 28: Genome Wide ICP4 Binding to Quiescent Genomes in MRC5 Cells 
Chromatin immunoprecipiation was used as before to isolate DNA bound by ICP4 following 
adenovirus superinfection of quiescently infected cells. The chromatin was prepared for alumina 
sequencing and aligned to the viral genome. Grey areas represent areas devoid of ICP4 
occupancy. The prominent peaks in the Mock, Ad0, and Ad4 samples correspond to poly T 
regions that likely map cellular reads.  
 
Activation of quiescent genomes in neurons by ICP4. 
 Since previous studies showed that neurons were relatively more permissive for viral 
transcription during quiescence, we wanted to determine if ICP4 alone could activate quiescent 
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d109 genomes in neurons. Therefore, the experiment depicted in Figure 25A was repeated in 
primary murine adult trigeminal neurons. The mapped reads aligned to the d109 genome are 
shown in Figure 29. When Ad0 was added to quiescently infected neurons, viral transcription 
was enhanced, similar to that seen in MRC5 cells, Figure 29. When ICP4 was added to ICP0 
expressing cells, viral transcription was greatly enhanced. The induction of viral genes by ICP4 
in the presence of ICP0 was more robust in neurons than MRC5 cells; while in MRC5 cells, viral 
transcription only increased by 1%, in neurons the percent viral transcripts increased from 2% to 
over 7% (data not shown). 
 
Figure 29: RNAseq of Quiescently Infected TG Neurons Superinfected with Adenovirus 
Trigeminal murine neurons were infected with d109, superinfected with adenovirus, and 
harvested as done with MRC5 cells. RNA was prepared for Illumina sequencing. Reads were 
mapped to the modified d109 genome as before.  
 
 118 
 At 24 hours, ICP4 functioned to more efficiently induce transcription from the quiescent 
genome in neurons, but not in MRC5 cells, despite a higher ICP4 transcript abundance in MRC5 
cells, Figure 30B. The mapped reads between mock and Ad4 infected cells are shown in Figure 
30A. The reads for mock and Ad4 in each cell type have been normalized to account for 
differences in the number of reads and the scales been modified to show similar profiles in the 
mock conditions so that differences in the Ad4 treatment can be visualized. The grey regions are 
areas of the genome devoid of transcripts. In neurons, provision of ICP4 led to an increase in 
viral transcription across the genome as the density of grey regions decreased, indicating more of 
the genome was being expressed. Additionally, several loci on the genome had notable increases 
in the density of viral reads. There were more mapped reads at UL1-4, UL27, UL29, UL30, 
UL39, UL40, and UL46, Figure 30A. However, in MRC5 cells, Ad4 did not lead to an increase 
in transcription, since the mapped read profiles of the mock and Ad4 treated cells were nearly 
identical. Additionally the fold increase between mock and Ad4 treatment was calculated for 
neurons and MRC5 cells and is shown in Figure 30C. The fold increase in viral reads is much 
larger in neurons than MRC5 cells, consistent with the read profiles. 
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Figure 30: Activation of Gene Expression by ICP4 in TG Neurons and MRC5 Cells 
Viral gene expression 24 hours post infection from quiescently infected MRC5 cells and neurons 
mock and Ad4 infected. A. Reads mapping to the viral genome. The reads for mock and Ad4 in 
each cell type have been normalized to account for differences in the number of reads. The scales 
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for neurons and MRC5 cells have been modified to show similar profiles in the mock conditions 
so that differences in the Ad4 treatment can be visualized. The grey regions are areas of the 
genome devoid of transcripts. B. Number of reads mapping to the ICP4 locus normalized to the 
total number of reads. C. Fold increase in the percentage of viral reads, calculated by dividing 
the percent reads of Ad4 by mock. D. Cufflinks analysis of viral transcripts. The mock samples 
were set to 1, and the values for the Ad4 conditions were obtained by dividing the number of 
reads in Ad4 by mock to determine the fold increase in expression. 
 
 The cufflinks software package was used to quantify the number of viral transcripts that 
mapped to each viral locus. The fold increase in gene expression between mock and Ad4 
treatments is shown from a few viral loci in Figure 30D. In neurons, ICP4 induced a statistically 
significant increase in the expression of several genes including UL4, UL12, UL29, UL39, 
UL41, UL46, UL48, US1, US6, and US10 along with several other genes (data not shown). The 
genes activated were mainly from the early and leaky late gene classes. Activation of late genes 
was not observed and was likely due to insufficient DNA replication. In MRC5 cells, the only 
transcript that was statistically significantly upregulated by ICP4 was UL29. ICP4 induced the 
expression of many viral genes in neurons but not in MRC5 despite the higher transcript 
abundance in MRC5 cells relative to neurons, demonstrating that ICP4 can function on quiescent 
genomes in neurons, but not in MRC5 cells.  
 
Binding of ICP4 to Quiescent Genomes in Neurons 
ICP4 did not activate or detectably bind to quiescent genomes in MRC5 cells. However, 
ICP4 alone was able to activate some viral genes to a relatively small extent in cultured neurons. 
Therefore, we hypothesized that ICP4 could bind to the quiescent genome. To test this, ChIP was 
performed on quiescent neurons to assess the binding of ICP4 in the presence and absence of 
ICP0, Figure 31. ICP4 bound to the genome in the absence of ICP0 at the TK promoter, but not 
the gC promoter. When ICP0 was present, the binding of ICP4 was seen at both the tk and gC 
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promoters. Therefore, ICP4 bound to the quiescent genome to some extent in the absence of 
ICP0 to activate transcription from the quiescent genome. As in MRC5 cells, the presence of 
ICP0 further promoted the binding of ICP4 to increase transcription. 
Figure 31: ICP4 Binding to Quiescent Genomes in TG Neurons 
Association of ICP4 with the A. TK and B. gC promoters, representative early and late gene 
promoters respectively, in quiescently infected TG neurons.  
3.6 DISCUSSION 
We have previously established RNAseq as a viable method to quantify transcription from the 
herpes genome during both productive and quiescent infection and have shown that cell type 
dependent differences in transcription from the quiescent state exist [87]. In these studies, we 
investigated the ability of the viral transcription factor ICP4 to bind to and initiate transcription 
from the quiescent state in MRC5 cells and TG neurons in the presence and absence of ICP0. 
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Since neurons were more permissive to d109 transcription, we hypothesized that ICP4 may by 
more efficient in activating transcription from quiescent genomes in neurons than in MRC5 cells. 
From these experiments, we have made the following conclusions: 1) ICP4 alone cannot induce 
transcription from the repressed genomes in MRC5 cells since it cannot access to quiescent 
genomes, 2) ICP0 enables ICP4 to bind to and transactivate viral genomes through inducing the 
removal of repressive chromatin, and 3) ICP4 can induce transcription from the quiescent 
genome in neurons in the absence of ICP0 since it can access these genomes in the absence of 
ICP0. 
 
ICP4 requires the presence of ICP0 to activate transcription from quiescent genomes in 
MRC5 cells 
During the establishment of quiescence, the viral genome acquires cellular histones that 
are modified through trimethylation of H3 at lysines 9 and 27, markers of heterochromatin [191]. 
Simultaneously, histone acetylation, a marker of active chromatin, decreases[346]. This 
epigenetic repression of the viral genome during latency may prohibit the binding of ICP4. ICP4 
binds to the viral genome through multimerization on several low affinity binding sites [77] and 
recruits cellular transcription factors and complexes to promote viral gene expression. Previous 
studies have shown that ICP4 can form complexes with multiple chromatin remodeling proteins, 
including the SWI/SNF and Ino80 complexes [79]. The Ino80 complex has the ability to slide 
nucleosomes and eject histones [398]. It has also been shown to be involved in transcription 
through chromatin and maintenance of an open chromatin state [399, 400]. The human SWI/SNF 
complex has been associated with both transcriptional activation and repression [401]. Despite 
its ability to interact with chromatin remodeling complexes, ICP4 did not activate transcription 
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from the quiescent state in MRC5 cells. RNAseq of Ad4 infected quiescently infected cells 
indicated no activation of quiescent genomes by ICP4, compared to AdZ control and mock 
infections, Figure 26A. The inability to activate transcription was due to the inability of ICP4 to 
bind to quiescent genomes. When ICP4 was present alone, ChIP at 2 viral promoters did not 
show association of ICP4 above background levels, Figure 27. Furthermore, when the 
association of ICP4 with the genome was assayed genome wide using ChIPseq, there was no 
ICP4 occupancy detected on the genome above background levels, Figure 28. The ChIP and 
ChIPseq data indicate that ICP4 cannot gain access to quiescent genomes.  
While ICP4 cannot activate transcription from genomes that have been silenced by the 
cells, it will function on genomes that have not been repressed. Previous studies using d109 have 
shown that GFP expressing cells can persist as long as 28 days [190]. GFP expressing MRC5 
cells can be seen in culture after 7 days, Figure 25A, but constitute a very small percentage of the 
total culture of less than .1%. As GFP is a marker of the epigenetic state of the viral genome, this 
population of GFP-expressing cells likely originates from viral genomes that have not been 
repressed by cellular heterochromatin or have been repressed to a much less extent. Detection of 
transcription from these cells using RNAseq is difficult since the vast majority of transcripts are 
cellular; in both AdZ and Ad4 treated cells, only a few hundred of the twenty million reads were 
virally derived. However, RT-PCR is transcript specific, and can detect very small changes in 
transcript abundance. RT-PCR analysis of a few viral genes showed that ICP4 alone induced the 
expression TK and VP16, (data not shown). Since this transcription is very low, and since ICP4 
cannot access genomes bound in chromatin, these transcripts are likely derived from the 
population of GFP expressing cells whose genomes have not been repressed in chromatin.  
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ICP0 enhances ICP4 transcription in MRC5 cells through epigenetic derepression of the 
genome 
Although ICP4 was unable to transactivate repressed genomes, it induced transcription 
from the quiescent genomes when ICP0 was present, Figure 26A. Studies have shown that when 
ICP0 is provided to quiescently infected cells, epigenetic silencing of the virus was removed: 
levels of trimethylated H3K9 decreased, histone occupancy was reduced, and histones remaining 
on the genome became more acetylated [222]. We found that ICP4 alone could not access the 
viral genome, but in the presence of ICP0, the binding of ICP4 to the viral genome was greatly 
enhanced. Additionally, the binding of ICP4 to the viral genome was inversely correlated to 
histone occupancy. When ICP4 was present alone, histone occupancy on the genome remained 
high, however, in the presence of ICP0, histone occupancy was significantly reduced. These 
results demonstrate that chromatin restricts the binding of ICP4 to the genome during quiescence 
and that ICP0 enables ICP4 to function through epigenetic derepression of the genome. 
 
ICP4 Activates Quiescent Genomes in Neurons 
Previous studies have shown that TG neurons are more permissive than MRC5 cells to 
transcription from the d109 genome during quiescence. We had hypothesized that this difference 
could be either due to differences in the epigenetic landscape of the cells or from the presence of 
insulator elements in the genome [87]. Insulator elements consist of core sequence of CCCTC 
that is bound by the CTCF protein [199]. Global studies of the human genome have shown 
CTCF elements to be a site of demarcation between active and repressed regions of chromatin 
[202]. Recently, seven CTCF elements have been identified in the HSV genome and are 
concentrated near the joint regions of the genome [203]. These insulator regions have been 
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shown to maintain chromatin boundaries between LAT and ICP0 during latency [204]. The 
presence of insulators would create a euchromatic region near the LAT locus, leaving the 
remainder of the genome largely heterochromatic. We have shown the regions near the insulator 
elements were more highly expressed in quiescently infected neurons [87], suggesting that these 
elements are responsible for the higher transcription near the joint regions in the genome. In 
these studies, however, there appears to be no bias as to what regions of the genome ICP4 can 
transactivate. ICP4 activated transcription globally in quiescent neurons, Figure 30A. There were 
increases in transcription near the joint regions and also within the unique long region, far away 
from the CTCF sites. While the CTCF elements may maintain higher transcription during 
quiescence, chromatin outside those regions did not prohibit activation by ICP4. This suggests 
that differences in repression efficiency exist between the two cell types.  
 The ability of ICP4 to activate transcription from quiescent genomes in neurons but not 
MRC5 cells is likely due to a difference in the epigenetic landscape of the two cell types. We 
propose a model, Figure 32, in which MRC5 cells have restricted the binding of ICP4 through 
constitutive heterochromatin occupancy on the genome, whereas in TG neurons, the genome is 
repressed in facultative heterochromatin, a less restrictive form of chromatin. This difference in 
chromatin structure may be due to differential expression of histone variants in the two cell 
types. The main H3 variants in non-neuronal cells (MRC5) are H3.1 and H3.2, which have been 
shown to be enriched in repressive markers [402]. However, during the differentiation of 
neurons, the expression of histone variants H3.1 and H3.2 become down regulated while H3.3 
expression is up regulated, making H3.3 the main histone variant present in neuronal chromatin 
[403, 404]. H3.3 has been shown to be associated with transcribed regions of the genome and is 
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absent from the inactivated X chromosome [402]. The different histone variants may also 
influence the type of heterochromatin deposited onto the quiescent genome. 
 
Figure 32: Model of ICP4 Action on Quiescent Genomes in MRC5 cells and TG Neurons.  
In MRC5 cells, constitutive heterochromatin blocks access of ICP4, preventing transcription of 
viral genes. When ICP0 is present, it derepresses and disperses chromatin, enabling binding and 
function of ICP4. In TG Neurons, facultative chromatin reduces, but not completely blocks, the 
binding of ICP4 to the genome. Thus, ICP4 can induce low levels of gene expression. When 
ICP0 is present, it removes chromatin, enhancing the function of ICP4.  
 
 Different types of heterochromatin have been observed on quiescent/latent genomes in 
MRC5 cells and neurons. During quiescence in MRC5 cells, the genome is bound by histones 
with trimentylated H3K9. HP1 association has also been observed [191]. HP1 recruits the 
methyltransferase Suv39h1 to promote the spread of heterochromatin [193, 405]. These 
modifications are indicative of constitutive heterochromatin, which is believed to be a more 
permanent form of repressive chromatin [406]. However, in neurons, in vivo studies have shown 
that as latency is established, trimethylation of H3K27 but not H3K9 is observed. Furthermore, 
the polycomb repressive complex 1, a complex responsible for maintaining facultative 
heterochromatin, subunit Bmi1 has been observed on genomes in latently infected neurons [118]. 
Facultative heterochromatin is a less restrictive and more regulatable form of chromatin [262].  
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 The more relaxed repression in neurons may enable more regulated control of the latent 
state. We have previously shown that there was a low level of transcription and specific 
upregulation of LAT in quiescently infected neurons. This study has shown that when ICP4 is 
present in quiescently infected neurons, it can bind to the quiescent genome and activate 
transcription across the quiescent genome. ICP0 can further induce transcription from the latent 
state by making the genome more accessible to ICP4. Uncontrolled expression of these two 
proteins could lead to frequent reactivation if left uncontrolled. The LAT transcript encodes 
several micro RNAs that target the ICP0 and ICP4 transcripts so that latency can be maintained 
[208, 210]. Fluctuations in the expression of LAT may lead to changes in ICP0 and ICP4 
expression to promote reactivation from latency. 
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4.0 SUMMARY OF THESIS AND GENERAL DISCUSSION 
4.1 SUMMARY OF THESIS 
HSV transcription heavily relies on cellular transcription machinery and chromatin remodeling 
and modifying complexes. During its lifecycle, HSV infects both epithelial and neuronal cells, 
productively replicating in epithelial cells and establishing and reactivating from latency in 
neurons. As these two cell types are in different stages in the cell cycle and transcribe different 
genes, they differ in their abundance of transcription factors and chromatin remodeling 
complexes. These differences may impact both viral transcription, and the ability of the virus to 
re-initiate lytic gene expression during reactivation from latency. A comprehensive study of the 
expression of viral genes in these two cell types had not been previously investigated. Nor has 
the ability of individual viral activators to induce reactivation from latency been studied. Thus, 
the aims of this study were to use RNA sequencing and ChIP to characterize wild type and 
mutant virus gene expression and to investigate the ability of ICP4 and ICP0 to induce 
transcription from quiescent genomes in these two cell types.  
To determine how cell type affected transcription of viral genes, RNAseq was used to 
quantify the viral transcription of both wild type and mutant viruses in MRC5 cells and TG 
neurons. Studies of productive infection with wild type virus showed that gene expression was 
similar in kinetics between neurons and MRC5 cells, but overall transcription was attenuated in 
neurons evidenced by less early and late gene transcription, possibly due to a decreased 
abundance of some cellular transcriptional activators used by the virus. The expression from 
d109, a viral mutant lacking immediate early genes, was highly attenuated and dysregulated in 
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both cell types. However, in the absence of immediate early genes, transcription was markedly 
different. Viral gene expression was approximately 10 times greater in neurons than MRC5 cells 
at all time points assayed. 
 To investigate how the level of repression of quiescent genomes affected the ability of the 
virus to reactivate in these two cell types, adenoviruses were used to deliver ICP0 and ICP4 to 
cells quiescently infected with d109 and RNAseq and ChIP/ChIPseq were used to quantify 
changes in gene expression and ICP4 binding, respectively. RNAseq studies showed that ICP4 
was unable to activate transcription from quiescent genomes in MRC5 cells. ICP0 enabled ICP4 
to induce gene expression through inducing the removal of chromatin from the genome, 
suggesting that in MRC5 cells, chromatin restricts access of ICP4 to the genome.  However, in 
neurons, ICP4 alone induced a low level of transcription from the genome and was able to access 
some promoters and not others, suggesting that the heterochromatin on quiescent genomes in 
neurons is less repressive and not uniform. The results of these studies suggest that latency is a 
more dynamic than previously thought, which allows a more delicate balance between the 
maintenance of latency and reactivation of the virus. These two areas will be discussed in greater 
detail in the following sections.  
 
4.2 GENERAL DICSUSSION 
 
Latency – A Dynamic State 
 
As d109 establishes quiescence in neurons and MRC5 cells, gene expression is highly 
dysregulated and attenuated. However, gene expression is approximately 10 times greater in 
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neurons than MRC5 cells. The majority of gene expression in neurons originated from loci 
within the unique short region and areas surrounding the joint region of the viral genome. The 
increased expression of these regions may be due to the presence of CTCF insulator elements in 
the genome, which serve as boundaries between areas of euchromatin and heterochromatin 
[202]. To date, seven CTCF elements have been identified in the HSV genome [203] and five of 
these elements are present in the d109 genome. It would be of interest to mutate these insulator 
elements and determine if gene expression changes during quiescence to establish a direct role of 
these elements in regulating expression from the quiescent genome.  
The greater level of transcription in neurons could be due to differences in the epigenome 
which would affect the ability of the cells to repress the viral gene expression. Studies have 
shown that as neurons differentiate, they express different histone variants, shifting from H3.1 
and H3.2 to H3.3 [403]. Nucleosomes containing the H3.3 variant have been shown to be 
enriched in euchromatic areas, associating them with active chromatin, while variants H3.1 and 
H3.2 are associated with repressed regions of chromatin [402]. The incorporation of this histone 
variant may promote the formation of facultative heterochromatin, rather than constitutive 
heterochromatin, on quiescent viral genomes. This form of chromatin is less repressive and can 
be reversed back to euchromatin following certain stimuli. The increased permissiveness of 
neurons to quiescent viral transcription may provide some insight as to why HSV evolved to 
establish a latent infection in neurons instead of epithelial cells. The expression of LAT and 
cellular repressors could serve to maintain the latent state, but not repress the genome too tightly 
to completely block the ability to reactivate.  
The latency associated transcript is specifically up-regulated in neurons, likely due to the 
presence of a neuron specific enhancer element in its promoter [364]. Early studies showed that 
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LAT expression reduced the abundance of immediate early transcripts in neuron cell lines [407]. 
Later studies showed that LAT codes for several microRNAs, several of which have been shown 
to target the ICP0 and ICP4 transcripts [210, 211]. More recent studies have shown that the 
deletion of miR-H2, the microRNA that targets ICP0, leads to increased neurovirulence and an 
increased rate of reactivation [212, 408]. The increased reactivation in the absence of miR-H2 
suggests that it may function to maintain the latent state.  
The specific upregulation of LAT in neurons may provide a mechanism to control lytic 
gene expression through targeting immediate early gene transcripts. However, fluctuations in 
LAT transcription could lead to a transient decline in LAT and thus microRNA abundance and 
could allow low levels of immediate early gene transcripts to accumulate. Since ICP4 can bind to 
the LAT promoter and inhibit LAT expression, this could begin to tip the balance to favor 
reactivation.  
 
Reactivation – Tipping the Balance 
 
Reactivation from latency has been an area of intense study, but a mechanism for this process 
has yet to be clearly elucidated. Recent data has suggested a two phase model of reactivation in 
which a burst of dysregulated global transcription is followed by the normal lytic cascade of viral 
gene expression culminating in the production of viral progeny. Additionally, the first phase of 
gene expression does not always lead to initiation of lytic expression and may serve as an 
additional point of control [217, 218]. However, this model and other models of reactivation use 
thermal stress and NGF withdrawal, and while they do efficiently induce reactivation of latent 
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virus in animal models, they may apply a much stronger reactivation stimulus than is what is 
experienced by individuals with recurring HSV breakouts.  
Our studies have shown that neurons are more permissive to HSV gene expression during 
quiescence and that LAT is specifically upregulated. In vivo studies of latency have shown that 
at least one lytic gene is expressed in two thirds of infected cells and that half of the infected 
cells have expression from more than one locus. Furthermore, lytic gene expression was directly 
correlated with increased expression of cellular antiviral genes, suggesting that the cell can detect 
increases in viral transcription and respond through activation of the cellular innate immune 
response to repress transcription. This opens the possibility that there is a low level of abortive 
reactivation during latency [409]. This suggests that stimuli that either decrease the cellular 
immune response or increase viral transcription could tip this balance to favor reactivation of the 
virus.  
Viral gene expression could be favored by transient decreases in LAT expression during 
latency. LAT expresses multiple microRNAs that have been shown to target the ICP0 and ICP4 
transcripts, preventing their accumulation [210]. Decreased expression of LAT would lead to a 
decrease in the abundance of these microRNAs, enabling ICP4 and ICP0 transcripts to 
accumulate and possibly be translated. Our studies have shown that ICP4 alone can bind to and 
activate transcription from the quiescent genome in neurons, which would lead to an increase in 
lytic gene transcription. ICP0 further enhances the activity of ICP4 by removing repressive 
chromatin from the genome, increasing ICP4 binding.  
In response to increases in viral transcription, the cell upregulates the expression of 
immune genes, resulting in an abortive reactivation event. However, ICP0 also targets multiple 
arms of the cellular innate immune response to prevent silencing of the genome. Studies have 
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shown that ICP0 is not required for the burst of gene expression preceding the lytic cascade, but 
is necessary for the production of infectious virus. It is possible that ICP0 functions during the 
second stage to block the innate immune response to prevent silencing of transcription and 
reestablishment of latency. It would be of interest to determine if the ability of ICP4 to induce 
transcription from the latent genome is dependent on cessation or reduction in innate immune 
signaling.  
Taken together these studies provide valuable insight into viral gene expression in the 
latent state and a possible mechanism for the reactivation of virus in the absence of external 
stressors. The increased permissiveness to viral transcription in neurons enables finer tuning of 
reactivation, through balancing lytic gene expression with the expression of the latency 
associated transcript and innate immune response. Increased expression of ICP4 and ICP0 could 
be caused from a decrease in LAT expression. ICP4 could function to promote lytic gene 
expression, while ICP0 could function to enhance ICP4 activity and block the cellular innate 
immune response to promote reactivation and the production of infectious virions. 
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5.0 FUTURE DIRECTIONS 
The next step in this project is to determine a reason for why neurons are more permissive to 
transcription than MRC5 cells. We have hypothesized that this difference may be due to 
differences in the chromatin deposited on the genome, in which neurons deposit facultative 
heterochromatin and MRC5 cells deposit constitutive heterochromatin. Facultative 
heterochromatin, but not constitutive heterochromatin, can be converted back to euchromatin 
under certain conditions. Recent studies have begun to link stress, both psychological and 
physiological, to changes in gene expression due to changes in chromatin modification [410]. If 
the genome is repressed by facultative heterochromatin in neurons, it is possible that cellular 
stress could induce a change in the epigenetic state of the viral genome from heterochromatic to 
euchromatin, facilitating reactivation of the virus.  
 Another possibility could be differences in the activation of the cellular innate immune 
response. In the absence of viral gene expression, HSV-1 induces the interferon response, 
leading to the upregulation of PML and Sp100, two components of the cellular ND10 complex. 
ICP0 degrades these complexes during lytic replication, but in latency, the viral genome is 
localized to these expanded structures and becomes silenced through the deposition of cellular 
heterochromatin [411]. If neurons are less able to induce the interferon response, they would 
express less of these restrictive proteins, leading to a decreased ability to repress the virus.   
We propose to use the d109 virus to determine both how the genomes are differentially 
repressed in neurons and MRC5, focusing on differences in the types of chromatin deposited 
onto the genome and in the induction of the host cell immune response. 
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 Epigenetic Differences between Cell Types 
In chapter 3, we suggested that the differential expression of histone variants may affect the type 
of chromatin deposited onto genomes, but due to the unavailability of antibodies specific to 
H3.1, H3.2, and H3.3, it is not possible to test this hypothesis without the use of transgenic cell 
lines expressing tagged histone variants. However, we can investigate the deposition of different 
forms of heterochromatin – facultative heterochromatin and constitutive heterochromatin in 
neurons and MRC5 cells, respectively. Chromatin can be prepared from quiescently infected 
cells and immunoprecipitated using antibodies to trimethylated H3K27 and trimethylated H3K9, 
markers of facultative and constitutive heterochromatin, respectively. An enrichment of 
trimethylated H3K27 in neurons and trimethylated H3K9 in MRC5 would support this 
hypothesis.  
 Additionally, it would also be of interest to determine why ICP4 could bind to some loci 
on the d109 genome in neurons but not others. This is most likely due to differences in local 
chromatin structure. To explore this possibility, ChIP using antibodies against histone H3, 
trimethylated H3K27 and trimethylated H3K9, as well as ICP4 will be used to correlate ICP4 
binding to chromatin medication. It would be especially interesting to do ChIP seq on neurons to 
compare genome wide histone occupancy, modification, and ICP4 binding. However, due to the 
low number of cells obtained from trigeminal ganglia culture, and the large number of cells 
necessary for this technique, this is not yet feasible.  
 Furthermore, if we find that neurons deposit mainly facultative heterochromatin and 
MRC5 cells deposit mainly constitutive heterochromatin, it would be of great interest to study 
how cellular stress can contribute to reactivation of the virus in neurons. NGF withdrawal has 
been shown to be sufficient to induce reactivation of latent virus. Quiescently infected neurons 
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will be treated with either LY294002, an inhibitor of the NGF signaling pathway, or vector 
control. RNA will be collected at 0, 4, 8, and 24 hours post infection and prepared for Illumina 
sequencing. If an upregulation of viral gene expression is detected, ChIP using antibodies against 
H3 and trimethylated H3K27 will be performed to determine if the increase in gene expression is 
correlated to changes in the chromatin state. 
 
Differences in Interferon Response  
To determine how the cellular response differs between cell types, both neurons and MRC5 cells 
will be infected with d109, and RNA will be harvested at 4, 8, and 24 hours post infection. A 
mock infected sample will also be collected for a baseline comparison. RNA will be prepared for 
Illumina sequencing. The reads will be aligned to the human genome for MRC5 cell samples and 
to the mouse genome for neuron samples using the cufflinks software package on the Galaxy 
server. The cuffcompare software package will be used to detect changes in gene expression 
between the mock infected and d109 infected samples and a list of genes that are significantly 
upregulated between mock and infected samples will be compiled for each cell type.   
 Since cuffcompare cannot compare differences in expression between samples from 
different species, the gene lists from neurons and MRC5 cells will need to be manually 
compared. To streamline this process and to determine if one particular set of genes is 
upregulated more in one cell type, genes will be grouped according to function, specifically 
focusing on interferon inducible genes and genes involved in chromatin modification. The focus 
will be looking for genes highly upregulated in MRC5 cells, but not in neurons. To determine if 
these genes contribute to the increased silencing of d109 genomes in MRC5 cells, highly induced 
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genes can be knocked down with siRNA prior to infection to determine the effect of their 
absence.  
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